Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites

Sasha V. Siegel^{4,2}, Roberto Amato^{4,3}, Hidayat Trimarsanto^{4,3}, Edwin Sutanto², Mariana Kleinecke², Kathryn Murie²
Georgia Whitton¹, Aimee R. Taylor⁸, James A. Watson^{9,10}, Mallika Imwong¹¹, Ashenafi Assef \mathcal{L} Georgia Whitton⁺, Aimee R. Taylor⁹, James A. Watson^{9,22},
Rahim^{9,13}, Nguyen Hoang Chau¹⁴, Tran Tinh Hien¹⁴, Justin
Day^{9,10}, Dominic P. Kwiatkowski^{1,10}, Julian C. Rayner¹⁶, Ric
² Wellcome Sanger Institute Rahim^{9.13}, Nguyen Hoang Chau¹⁴, Tran Tinh Hien¹⁴, Justin A Green¹⁵, Gavin Koh¹⁵, Nicholas J. White^{9,10}, Nicholas
Day^{9,10}, Dominic P. Kwiatkowski^{1,10}, Julian C. Rayner¹⁶, Ric N. Price^{29,10} and Sarah Aub

Rahim^{9.13}, Nguyen Hoang Chau²⁴, Tran Tinh Hien²⁴, Justin A Green²⁵, Gavin Koh²⁵, Nicholas J. White^{9,25}, Nicholas
Day^{9,10}, Dominic P. Kwiatkowski^{1,10}, Julian C. Rayner¹⁶, Ric N. Price^{29,10} and Sarah Aubu Day"¹⁰, Dominic P. Kwiatkowski⁴¹⁴⁶, Julian C. Rayner⁴⁶, Ric N. Price^{2,7,20} and Sarah Auburn⁴¹⁷
¹ Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK
² Menzies School of Health Research and Charles Darw ² Wellcome Sanger Institute, Hinxton, Cambridge CB10 1SA, UK

² Menzies School of Health Research and Charles Darwin Univer

³ MRC Centre for Genomics and Global Health, Big Data Institute

⁴ Eijkman Institute for 8 MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK

⁴ Eijkman Institute for Molecular Biology, National Research and Innovation Agency, Jakarta 10430

⁵ Exeins Health I

⁻ Menzies School of Health Research and Charles Darwin University, Darwin, Northern Territory 0811, Australia
³ MRC Centre for Genomics and Global Health, Big Data Institute, University of Oxford, Oxford, UK
⁴ Eijkma ⁵ Eijkman Institute for Molecular Biology, National Research and Innovation Agency, Jakarta 10430, Indonesia
⁵ Exeins Health Initiative, Jakarta Selatan 12870, Indonesia
⁸ Institut Pasteur, University de Paris, Infec $^{\circ}$ Institut Pasteur, University de Paris, Infectious Disease Epidemiology and Analytics Unit, Paris, France
 $^{\circ}$ Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Ba

⁵ Exeins Health Initiative, Jakarta Selatan 12870, Indonesia

⁸ Institut Pasteur, University de Paris, Infectious Disease Epidemiology and Analytics Unit, Paris, France

⁹ Mahidol-Oxford Tropical Medicine Research U F Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok
10400, Thailand
¹⁰ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University o ¹⁰ Centre for Tro_l
7U, UK
¹¹ Department of
Bangkok, Thailan
¹² Ethiopian Publi
¹³ Nangarhar Me

²⁰ Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, OX3
7LJ, UK
¹¹ Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol Uni ¹¹Depar
¹¹Depar
Bangkol
¹² Ethio_l
¹³ Nanga
¹⁴ Oxfor
Minh Ci
¹⁵ Glaxo ⁻⁻Department of Molecular Tropical Medicine and Genetics, Faculty of Tropical Medicine, Mahidol University,
Bangkok, Thailand
¹² Ethiopian Public Health Institute, Addis Ababa, Ethiopia
¹³ Nangarhar Medical Faculty, ¹² Ethiopian Public
¹³ Nangarhar Media
¹⁴ Oxford University
Minh City, Vietnam
¹⁵ GlaxoSmithKline, ¹¹ Ethiopian Public Health Institute, Addis Ababa, Ethiopia¹³
¹³ Nangarhar Medical Faculty, Nangarhar University, Minis
¹⁴ Oxford University Clinical Research Unit, Hospital for Tro
Minh City, Vietnam
¹⁵ GlaxoSmi ²⁵ Nangarhar Medical Faculty, Nangarhar University, Ministry of Higher Education, Afghanistan
¹⁴ Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, W.1
Minh City, Vietnam
¹⁵ G

⁻⁻ Oxford University Clinical Research Unit, Hospital for Tropical Diseases, 764 Vo Van Kiet, W.1, Dist.5, Ho Chi
Minh City, Vietnam
¹⁵ GlaxoSmithKline, Brentford, UK
¹⁶ Cambridge Institute for Medical Research, Univ Minh City, Vietnam
¹⁵ GlaxoSmithKline, 1
¹⁶ Cambridge Institu
*Corresponding aut
PO Box 41096, Casu ¹⁶ GlaxoSmithKline, Brentford, UK
¹⁶ Cambridge Institute for Medical
*Corresponding author: Dr Sarah
PO Box 41096, Casuarina, Darwin, ²⁰ Cambridge Institute for Medical Research, University of Cambridge, Hills Road, Cambridge, CB2 0XY, UK
*Corresponding author: Dr Sarah Auburn, Sarah.Auburn@Menzies.edu.au, Menzies School of Health Rese
PO Box 41096, Ca $\ddot{}$ *Corresponding author: Dr Sarah Auburn, Sarah Auburn, Sarah.Auburn, Menzies.edu.au, Menzies.edu.au, Menzies.edu
PO Box 41096, Casuarina, Darwin, NT 0811, Australia; Tel: (+61) 8 8946 8503 PO Box 41096, Casuarina, Darwin, NT 0811, Australia; Tel: (+61) 8 8946 8503

Abstract

)
}
} } } Challenges in understanding the origin of recurrent Prosincular Vivax infections constrains the survenance or
antimalarial efficacy and transmission of this neglected parasite. Recurrent infections within an individual may arise from activation of dormant liver stages (relapse), blood-stage treatment failure (recrudescence) or new
inoculations (reinfection). Molecular inference of familial relatedness (identity-by-descent or IBD) based on wh ariso from action of the interation of the interation of familial relatedness (identity-by-descent or IBD) based on w
genome sequence data, together with analysis of the intervals between parasitaemic episodes ("time-to-ev genome sequence data, together with analysis of the intervals between parasitaemic episodes ("time-to-event"
analysis), can help resolve the probable origin of recurrences. Whole genome sequencing of predominantly low-
den analysis), can help resolve the probable origin of recurrences. Whole genome sequencing of predominantly low-
density P. vivax infections is challenging, so an accurate and scalable genotyping method to determine the orig density P. vivax infections is challenging, so an accurate and scalable genotyping method to determine the origin
of recurrent parasitaemia would be of significant benefit. We have developed a P. vivax genome-wide informa density P. *Vivax* infections is challenging, so an accurate and scalable genotyping inethicd to determine the origins
of recurrent parasitaemia would be of significant benefit. We have developed a *P. vivax* genome-wide pipeline to select specific microhaplotype panels that can capture IBD within small, amplifiable segments of the
genome. Using a global set of 615 *P. vivax* genomes, we derived a panel of 100 microhaplotypes, each compri physical select specific microhaplotypes, we derived a panel of 100 microhaplotypes, each comprisin
3-10 high frequency SNPs within <200 bp sequence windows. This panel exhibits high diversity in regions of the
Asia-Pacif genome. Osing a global set of 615 P. *With* genomes, we derived a panel of 100 microhaplotypes, each comprising 3-10 high frequency SNPs within <200 bp sequence windows. This panel exhibits high diversity in regions of th **3** a - Pacific, Latin America and the horn of Africa (median $H_E = 0.70-0.81$) and it captured 89% (273/307) of the polyclonal infections detected with genome-wide datasets. Using data simulations, we demonstrate lower er Asia Facinc, Latin America and the horn of Africa (median H_E = 0.70–0.01) and it captured 89% (273/307) of the
polyclonal infections detected with genome-wide datasets. Using data simulations, we demonstrate lower erro
i polyclonal in estimating pairwise IBD using microhaplotypes, relative to traditional biallelic SNP barcodes. Our panel
exhibited high accuracy in predicting the country of origin (median Matthew's correlation coefficient > in exhibited high accuracy in predicting the country of origin (median Matthew's correlation coefficient >0.9
countries tested) and it also captured local infection outbreak and bottlenecking events. The informatics p
is a exhibited high accuracy in predicting the countries tested) and it also captured local infection outbreak and bottlenecking events. The informatics pipeline is available open-source and yields microhaplotypes that can be r is available open-source and yields microhaplotypes that can be readily transferred to high-throughput amplicon
sequencing assays for surveillance in malaria-endemic regions.
Ke**y words**
Plasmodium vivax, malaria, recurren

Key words

is available open states and yields microhaplotypes that can be readily transferred to higherman sequencing assays for surveillance in malaria-endemic regions.
 Key words
 Plasmodium vivax, malaria, recurrence, relapse, sequencing assays of the sequencity of the Mey Words
Plasmodium vivax, malaria, recurrence, relapse, relatedness, ge
barcode, molecular surveillance Plasmodium vivax, malaria, recurrence, relapse, relatedness, genotyping, identity-by-descent, microhaplotype, Plasmodium vivax, malaria, recurrence, relapse, relatedness, genotyping, identity‐by‐descent, microhaplotype,
barcode, molecular surveillance barco, molecular surveillance
 barcode, molecular surveillance
 barcode, molecular surveillance
 barcode, molecular surveillance

Introduction

The malaria parasite Plasmodium vivax is a major public health threat affecting the poorest and most vulnerable The malaria parasite Plasmodium vivux is a major public health threat affecting the poorest and most vulnerable
populations in more than 49 endemic countries¹. Over the past decade, enhanced malaria control efforts in ar populations in more than 49 endemic countries¹. Over the past decade, enhanced malaria control efforts in areas
outside of sub-Saharan Africa have achieved a marked decline in *P. falciparum* infections, but a relative r arked decline in *P. falciparum* infections, but a relative rise in the
ttributes of *P. vivax* render this species more resilient to
dormant liver stage parasites (hypnozoites) that can reactivate
recurrent episodes of ma outside of sub-Saharan Africa have achieved a marked decline in P. Julefyar am infections, but a relative rise in the
proportion of P. vivax cases¹. Several biological attributes of P. vivax render this species more resi proportion of *P. vivax* cases⁻
interventions than *P. falcipa.*
weeks to months after initia
inoculation can cause multip
cause over 60% of clinical ca
underlying reactivation mecl
strategies to combat this pai
increase . Several biological attributes of P. *WWA* render this species indic resilient to rum². P. *vivax* forms dormant liver stage parasites (hypnozoites) that can read inoculation causing recurrent episodes of malaria (rela interventions than *P. falciparum*
weeks to months after initial inoc
inoculation can cause multiple re
cause over 60% of clinical cases³.
underlying reactivation mechanis
strategies to combat this parasite
increased und . P. vivax forms dormant liver stage parasites (hypnozoites) that can reactivate culation causing recurrent episodes of malaria (relapses). A single mosquito lapses, sustaining transmission over extended periods. Relapses inoculation can cause multiple relapses, sustaining transmission over extended periods. Relapses are though
cause over 60% of clinical cases³. Knowledge of the biology and epidemiology of *P. vivax* relapse, including th inculation cause over 60% of clinical cases³. Knowledge of the biology and epidemiology of *P. vivox* relapse, including the underlying reactivation mechanism(s) and host and parasite determinants, are vital for informin cause over 60% of clinical cases"
underlying reactivation mechani
strategies to combat this parasit
increased understanding has bee
recurrences can arise from reinfi
failures), or relapse (reactivation
Accurate methods to . Knowledge of the biology and epidemiology of P. *Wook* Telapse, including the sm(s) and host and parasite determinants, are vital for informing public health e, but our understanding of these processes is limited⁴. A strategies to combat this parasite, but our understanding of these processes is limited⁴. A major obstacle to our
increased understanding has been the difficulty of classifying recurrent *P. vivax* infections accurately. strategies to combat this parasite, but our understanding of these processes is limited⁻⁻
increased understanding has been the difficulty of classifying recurrent *P. vivax* infectic
recurrences can arise from reinfectio ons accurately. These

bod-stage treatment

e causes is challenging.

re critical to improving ou

ccumulating reports

ges, is failing in several

increased understanding has been the difficulty of classifying recurrent P. Vivax infections accurately. These
recurrences can arise from reinfection (new mosquito inoculations), recrudescence (blood-stage treatment
failur recurrences), or relapse (reactivation of dormant liver stages). Discriminating between these causes is challenging
Accurate methods to disentangle relapse from reinfection and recrudescence events are critical to improvin Facturate methods to disentangle relapse from reinfection and recrudescence events are critical to improving conderstanding of the therapeutic efficacy of current treatment regimens for *P. vivax.* Accumulating reports sug ノ l s 6 / F F Accurate methods of the therapeutic efficacy of current treatment regimens for *P. vivax.* Accumulating reports suggest that chloroquine, the most widely used drug for treating the *P. vivax* blood stages, is failing in se understanding of the therapeutic efficacy of editent treatment regimens for P. Wiva. Accumulating reports
suggest that chloroquine, the most widely used drug for treating the *P. vivax* blood stages, is failing in sever
en suggest that chloroquine, the most wheely used drug for treating the P. vivax blood stages, is failing in several
endemic regions, but recrudescence (drug failure) can be confused with relapse, confounding efficacy studies endemic regions, but recrudescence (drug failure) can be confused with relapse, confounding efficacy studies²
Accurate diagnosis of the cause of recurrent infection is also essential to clinical studies of hypnozoiticida i
e
h relapse) regimens (primaquine and tafenoquine) as this relies on distinguishing relapse from reinfection^{6,7}.
Reinfection dilutes observed differences in recurrence between hypnozoiticidal interventions and biases
treatme

relapse) regimens (primaquine and tafenoquine) as this relies on distinguishing relapse from reinfection^{9,7}.
Reinfection dilutes observed differences in recurrence between hypnozoiticidal interventions and biases
treatme The ability to discriminate between recurrent *P. falciparum* infections deriving from reinfections (which a
The ability to discriminate between recurrent *P. falciparum* infections deriving from reinfections (which a
gene treatment effect estimates towards interventions which provide longer post-treatment prophylaxis"
The ability to discriminate between recurrent *P. falciparum* infections deriving from reinfections (wh
genetically heterolo .
הח
.
את
.s ∏ aww.cc.cc.i The ability to discriminate between recurrent P. Junciparum infections deriving from reinfections (which are likely
genetically heterologous to the initial infection given sufficient population diversity) and recrudescence generally heterologous parasites) using genotyping at a handful of polymorphic markers, represented a crucial
advance for *P. falciparum* clinical research⁹. It allowed therapeutic efficacy studies to be conducted in end contained for *P. falciparum* clinical research⁹. It allowed therapeutic efficacy studies to be conducted in endem
areas without the need for concomitant detailed epidemiological assessment. However, the situation is mor advance for *P. falciparum* clinical research". It allowed therapeutic efficacy studies to be conducted in endemic
areas without the need for concomitant detailed epidemiological assessment. However, the situation is more
 are are alternative the need for *P. vivax* malaria since relapsing parasites can be genetically homologous or heterologous to the initection^{10,11}. However, recent genomic studies have revealed that a proportion of paire complex for P. vivax malaria since relapsing parasites can be genetically nomologous or neterologous to the initial
infection^{10,11}. However, recent genomic studies have revealed that a proportion of paired *P. vivax* is infection²⁰¹². However, recent genomic studies have revealed that a proportion of paired *P. vivax* isolates (from
acute and recurrent infections) that would be classified as heterologous using traditional genotyping ap share homology in large segments of the genome, inferring familial relatedness¹²⁻¹⁴. In mosquito hosts capturing
blood meals with mixtures of parasite genomes, the obligate meiotic stage will generate meiotic recombinan share homology in large segments of the genome, inferring familial relatedness²²²². In mosquito hosts capturing
blood meals with mixtures of parasite genomes, the obligate meiotic stage will generate meiotic recombinan blood meals with mixtures of parasite genomes, the obligate meiotic stage will generate meiotic recombinants, producing sporozoites that share parents. Every natural infection deriving from more than one sporozoite may co comprise mixtures of meiotic recombinants. Pairs of infections with evidence of recent identity by descent (IBD
consistent with close relationships such as siblings or half-siblings (as much as \geq 50% and \geq 25% IBD r consistent with close relationships such as siblings or half-siblings (as much as \geq 50% and \geq 25% IBD respectively), are more likely to have derived from the same mosquito inoculation than from different inoculation are more likely to have derived from the same mosquito inoculation than from different inoculations and are,
therefore, more likely to reflect relapse than reinfection events. IBD therefore has significant potential to en are more likely to reflect relapse than reinfection events. IBD therefore has significant potential to enak
more accurate classification of recurrent *P. vivax* infections. IBD-based measures would also allow finer resolu
 therefore, more accurate classification of recurrent *P. vivax* infections. IBD-based measures would also allow finer resolution
of the spatial connectivity between *P. vivax* populations than is possible using classical m more accurate classification of recurrent P. vivax infections. IBD-based measures would also allow mier resolution
of the spatial connectivity between *P. vivax* populations than is possible using classical methods such as Fixation index or phylogenetic approaches¹⁵. With appropriate genetic data, IBD can be used to characterise
fixation index or phylogenetic approaches¹⁵. With appropriate genetic data, IBD can be used to characterise fixation index or phylogenetic approaches*". With appropriate genetic data, IBD can be used to characterise major
3

across borders.
While genomic data provides the greatest information to estimate IBD, *P. vivax* patient isolates often have low
parasite densities which currently precludes whole genome sequencing at large scale, even whe While genomic
parasite densitie
whole genome a
as these are aty
infections. High
volume samples ハ ド ミ i ハ r While genomic data provides the greatest information to estimate IBD, *P. Vivax* patient isolates often have low
parasite densities which currently precludes whole genome sequencing at large scale, even when using selectiv whole genome amplification methods¹⁶. Restricting analyses to infections with high parasite densities is not ideal
as these are atypical of *P. vivax* infection and hence may not be representative of the true diversity whole genome amplification methods²⁷. Restricting analyses to infections with high parasite densities is not ideal
as these are atypical of *P. vivox* infection and hence may not be representative of the true diversity as these are atypical of P. *Wivax* infection and hence may not be representative of the true diversity in patient
infections. High-throughput genotyping offers a more operationally feasible approach that can be applied to inference in the samples such as dried blood spots and would be more readily implemented in surveillance frameworks in
malaria-endemic countries¹⁷. However, selecting parsimonious marker sets that can capture genome wide volume samples such as dried blood spots and worker sets that can capture genome wide IBD
effectively is challenging¹⁸. To date, genotyping methods for *P. vivax* have relied on either capillary sequencing of
microsatel malaria-endemic countries⁻'. However, selecting parsimonious marker sets that can capture genome wide IBD
effectively is challenging¹⁸. To date, genotyping methods for *P. vivax* have relied on either capillary sequenc effectively is challenging²⁸. To date, genotyping methods for *P. vivax* have relied on either capillary sequencing of
microsatellite markers or next generation sequencing (NGS) of Single Nucleotide Polymorphisms (SNPs) microsatellite markers or next generation sequencing (NGS) of Single Nucleotide Polymorphisms (SNPs)⁻
recent *P. falciparum* study, targeted NGS of short regions comprising multiple highly variable SNPs
(microhaplotypes) . In a
ing, w
ate IBI
D

recent P. *Juleiparum* study, targeted NGS of short regions compirsing multiple highly variable SNPs¹⁹.
(microhaplotypes) provided a simpler, cheaper, and higher-throughput approach than microsatellit
substantially highe (microhaplot) provided a simpler) provided a simpler microhapler microhaples).

Substantially higher resolution of individual clones than with single SNPs¹⁹.

Using 1,816 publicly available *P. vivox* genomes, we identif substantially higher resolution of individual clones than with single SNPs²⁹.
Using 1,816 publicly available *P. vivax* genomes, we identified microhaploty
across pairs of infections in diverse parasite populations. The しらしょう Using 1,016 publicly available P. Vivax genomes, we identified interomaple type markers that codid estimate IBD
across pairs of infections in diverse parasite populations. The goal was to establish a universal P. vivax IBD across pairs of infections in diverse parasite populations. The goal was to establish a universal P. *Vivax* IBB
barcode to improve the interpretation of therapeutic evaluations of hypnozoiticidal and schizonticidal
antima antimalarial drugs, elucidate the biology and epidemiology of *P. vivax* relapses, and provide NMCPs and
agencies with actionable information on parasite transmission within and across national borders. *In si*
analyses co antimalarial drugs, elucidate the biology and epidemiology of P. Vivax relapses, and provide NMCP 3 and other
agencies with actionable information on parasite transmission within and across national borders. In silico
anal agencies with actionable information on parasite transmission within and across national borders. In sinco
analyses confirmed that *P. vivox* microhaplotypes can provide much higher resolution to estimate relatedn
consiste analyses committed that P. vivax microhaplotypes can provide much higher resolution to estimate relatedness
consistent with close relationships compared to biallelic SNP barcodes that are currently used.
Results
Microhaplo

Results

Microhaplotype candidate selection

consistent with close relationships compared to biallelic SNP barcodes that are currently used.
Results
From an initial set of 1,816 isolates from the MalariaGEN Pv4 data release (Figure 1a), we ident $\begin{array}{c} 1 \\ 1 \\ 2 \end{array}$ From an initial set of 1,816 isolates from the MalariaGEN Pv4 data release (**Figure 1a**), we identified 615 high
quality apparently monoclonal infection samples (>50% genome positions callable, *Fws* \geq 0.95)²⁰. This quality apparently monoclonal infection samples (>50% genome positions callable, *F*ws ≥0.95)²⁰. This sample set was used to select variants and identify potential microhaplotype candidate regions for targeted sequencin was used to select variants and identifying 200 bp regions of the *P. vivox* genome with high diversity in isolates from all geographic regions. In addition to country classifications, the samples were assigned regional po the aim of identifying 200 bp regions of the P. *vivax* genome with high diversity in isolates from all geographic
regions. In addition to country classifications, the samples were assigned regional population classificati regions. In addition to contribute MalariaGEN PV4 project and based on genetic clustering patterns²⁰. Although most parasit
were from the Asia-Pacific region, the sample set exhibited broad geographic representation, spa derived from the MalariaGEN Pv4 project and based on genetic clustering patterns²⁰. Although most parasites
were from the Asia-Pacific region, the sample set exhibited broad geographic representation, spanning 17
countri

were from the Asia Figure from the Langley of a material of 2-graphic representation, spanning 3-
countries and with all regional populations represented by at least 30 isolates (range n=31-151) (**Table 1,**
Supplementary F countries and with all regional populations represented by at least 30 isolates (range n=31-151) (Table 1, Supplementary Figure 1).
Supplementary Figure 1).
A total of 13,090 candidate high quality biallelic SNPs with glob Supplementary Figure 1).
A total of 13,090 candidate
frequency (MAF >0.1) and
genome (excluding hyperv
(Figure 1b). We then cond
scanning increments) acro
windows were relatively u ノイ fl w y y Frequency (MAF >0.1) and low genotype failure rate (missingness < 0.1) were identified in coding regions of genome (excluding hypervariable regions) to minimise potential changes in primer-binding sites and missire (Figur Figure 1b). We then conducted a windowed scan in partially overlapping windows (200 bp windows, 50 bp
(Figure 1b). We then conducted a windowed scan in partially overlapping windows (200 bp windows, 50 bp
scanning incremen Figure 1b). We then conducted a windowed scan in partially overlapping windows (200 bp windows, 50 bp
scanning increments) across all identified variants of interest (39,280 windows). As illustrated in Figure 1c, these
wi (Figure 1b). We then conducted a windowed scan in partially overlapping windows (200 bp windows, 50 bp scanning increments) across all identified variants of interest (39,280 windows). As illustrated in **Figure 1c**, the w scanning increments) across all identified variants of interest (39,280 windows). As indstrated in Figure 1c, these
windows were relatively uniformly distributed across the genome. We then filtered further by heterozygosit windows were relatively uniformly distributed across the genome. We then filtered function \mathcal{A}

5,460 microhaplotype candidate "heterozygome windows" within the nuclear genome. Of these candidates, 2
microhaplotypes with roughly even spacing across all 14 chromosomes were chosen for further panel evaluat
that each co Somicrohaplotypes with roughly even spacing across all 14 chromosomes were chosen for further panel evaluation
that each contained between 3-10 candidate SNPs, optimised for highest heterozygosity (High-diversity SNP
panel that each contained between 3-10 candidate SNPs, optimised for highest heterozygosity (High-diversity SNP
panel: mean het = 0.82, min = 0.61, max = 0.96). A second panel of 100 randomly selected microhaplotypes
(Random-SNP panel: mean het = 0.82, min = 0.61, max = 0.96). A second panel of 100 randomly selected microhaplotypes
(Random-SNP panel: containing any number of SNPs, heterozygosity > 0.5, evenly spaced) was also included
comparative Frandom-SNP panel: containing any number of SNPs, heterozygosity > 0.5, evenly spaced) was also included
comparative analysis to investigate the impact of heterozygosity in panel informativeness for several use ca:
(Figure comparative analysis to investigate the impact of heterozygosity in panel informativeness for several use cases
(Figure 1d). Details on the coordinates, SNPs and genes covered by the High-diversity and Random-SNP
microhap (Figure 1d). Details on the coordinates, SNPs and genes covered by the High-diversity and Random-SNP
microhaplotype panels are provided in Supplementary Table 1. The two hypothetical microhaplotype panels
(High-diversity (Figure 1d). Details on the coordinates, SNP's and genes covered by the High-diversity and Nandom-SNP
microhaplotype panels are provided in Supplementary **Table 1**. The two hypothetical microhaplotype pa
(High-diversity SN micronaplotype panels are provided in Supplementary Table 1. The two hypothetical micronaplotype panels
(High-diversity SNP panel, Random-SNP panel) as well as a previously developed biallelic SNP panel (the 42-S
Broad bar (High and Unity Panel) and the panel) as the Higheral parallelic process with IBD estimation amon

real and simulated infection pairs. Four SNPs within the Broad barcode had to be excluded from analyses becaus

of high gen Broad barcode)²¹ were then benchmarked for their ability to discriminate relatedness with IBD estimation among
real and simulated infection pairs. Four SNPs within the Broad barcode had to be excluded from analyses becau real and simulated infection pairs. For the three pairs of infections across a present from and to be excluded to be

Effective estimation of identity by descent with microhaplotype panels

of high genotype failure rates (i.e., less than 5 reads covering the SNP in >10% of the available global?). Would
sample set), or multi-allelic status (i.e., not bi-allelic). This left 38 SNPs for evaluation; herein we ref sample set), or multi-allelic tend (i.e., not bic status (i.e., not bic status (i.e., not bic status (i.e., no
as the 38-SNP Broad barcode.
A formal evaluation of identity by descent with microhaplotype panels
A formal ev **Effective estimation of identit**
A formal evaluation of the acci
was first conducted using simu
using the *paneljudge* package²
geographic region, the 95% co A formal evaluation of the accuracy of the three panels to estimate IBD between monoclonal P. Work infections

was first conducted using simulated data generated on pairs of infections across a range of relatedness. In ea was figure the paneljudge package²². All data were simulated under the model used to estimate relatedness. In each geographic region, the 95% confidence intervals (CIs) around the estimate \hat{r} were calculated as a m using the *paneljudge* package²². All data were simulated under the model used to estimate relatedness. In each
geographic region, the 95% confidence intervals (CIs) around the estimate \hat{r} were calculated as a meas geographic region, the 95% confidence intervals (CIs) around the estimate \hat{r} were calculated as a measure of the informativeness of a given marker panel (**Figure 2**). In all geographic regions and for all marker pane intervals were shortest when r=1 (identical infections), closely followed by r=0 (strangers), and highest when r=0.5 (siblings) indicating lowest accuracy in predicting sibling relationships. In all geographic regions, the intervals were shortest when r=1 (identical infections), closely followed by r=0 (strangers), and inghest when
r=0.5 (siblings) indicating lowest accuracy in predicting sibling relationships. In all geographic regions, the Examples were shortest around the estimate \hat{r} at the High-Diversity SNP microhaplotype panel followed by the
andom-SNP microhaplotype panel, and the 38-SNP Broad barcode. At the High-Diversity panel, all (100%) of
es Intervals were shortest around the estimate *f* at the High-Diversity SNP inicionalplotype panel ronowed by the
Random-SNP microhaplotype panel, and the 38-SNP Broad barcode. At the High-Diversity panel, all (100%) of t
es Random-SNP microhaplotype panel, and 0.8. Whilst the Random-SNP microhaplotype panel followed
similar trends to the High-diversity SNP panel in each geographic region, the Broad barcode displayed particularly
large CI inte estimilar trends to the High-diversity SNP panel in each geographic region, the Broad barcode displayed particular
large CI intervals relative to the microhaplotype panels in Maritime Southeast Asia and Oceania. The same t large CI intervals relative to the microhaplotype panels in Maritime Southeast Asia and Oceania. The same trends
in marker panel performance were observed using the root mean squared error (RMSE) of the estimates of $r(\hat{$ In marker panel performance were observed using the root mean squared error (RMSE) of the estimates of r (\hat{r}) compared to the data-generating r (**Supplementary Figure 2**). In all regions, the High-diversity SNP m In marker panel performance were observed using the root mean squared error (RMSE) of the estimates of *r* (*r*)
compared to the data-generating *r* (**Supplementary Figure 2**). In all regions, the High-diversity SNP
microh compared to the data generating *r* (supplementary Figure 2). In all regions, the High⁻diversity SNP microhaplotype panel exhibited consistently lower RMSE values than the Random-SNP microhaplotype more accurate estimati micropertype panel exhibited consistently lower and that panels of ~100 uniformly spaced microhaplotypes provide
more accurate estimation of IBD than the current single SNP panel used for *P. vivax* infections; this advant These results in the current single SNP panel used for *P. vivax* infections; this advantage
may be more pronounced in certain geographic regions, possibly reflecting the geographic representation
informing SNP selection.

may be more pronounced in certain geographic regions, possibly reflecting the geographic representation
informing SNP selection.
In addition to the simulated data, the efficacy of the three panels in estimating IBD between informing SNP selection.
In addition to the simulated data, the efficacy of the three panels in estimating IBD between infections was
evaluated using 'real' data from sequenced pairs of primary and recurrent *P. vivax* in In addition to the simulat
evaluated using 'real' dat
came from a range of clir
the criteria for selection i
points. The infection pair
range of durations betwe | ((t
| | | evaluated using 'real' data from sequenced pairs of primary and recurrent *P. vivox* infections. These samples
came from a range of clinical trials, as well as from returning travellers²³⁻²⁶. A total of 14 infection pai evaluated using 'real' data from sequenced pairs of primary and recurrent P. Weak infections. These samples came from a range of clinical trials, as well as from returning travellers²³⁻²⁶. A total of 14 infection pairs s came from a range of clinical trials, as well as from returning travellers²³-26. A total of 14 infection pairs satisfied
the criteria for selection which required monoclonal infections with high-quality genomic data at b points. The infection pairs originated from a range of geographic locations in the Asia-Pacific and exhibited a
range of durations between the primary and recurrent episode (**Table 2**). Genome-wide IBD measures using
 $hmmIB$ points. The infection pairs of the infection pairs of the infection pairs of the infection pairs of the primary and recurrent episode (Table 2). Genome-wide IBD measures using

htmmIBD revealed that 11 infection pairs were hmm/BD revealed that 11 infection pairs were clones (IBD \geq 0.95) reflecting potential recrudescence or relaps
 hmm/BD revealed that 11 infection pairs were clones (IBD \geq 0.95) reflecting potential recrudescence or re hmmIBD revealed that 11 infection pairs were clones (IBD ≥0.95) reflecting potential recrudescence or relapse

relatives and strangers reflect potential reinfection or relapse events. When the data were restricted to the 10
microhaplotype markers, the resulting *hmmIBD*-based estimates correlated highly with the genome-wide
measure microhaplotype markers, the resulting *hmmIBD*-based estimates correlated highly with the genome-wide
measures of IBD (rho=0.790, Spearman's rank correlation). One pair of infections (PJ0167-C and PJ0166-C) that
were class meronaplotype markers, the resulting *minimab* based estimates correlated ingity with the genome wide
measures of IBD (rho=0.790, Spearman's rank correlation). One pair of infections (PJ0167-C and PJ0166-C)
were classified

Microhaplotype panels can effectively capture diversity and differentiation

were classified as strangers with genomic data (IBD = 0.048) were classified as distant relatives (IBD = 0.156) with
the microhaplotypes, but the other 13 pairs had concordant recurrence classifications.
Microhaplotype pa the microhaplotypes, but the other 13 pairs had concordant recurrence classifications.
 Microhaplotype panels can effectively capture diversity and differentiation

Further evaluation of the highest performance panel, th **Microhaplotype panels can effectively capture diversity and differentiation**
Further evaluation of the highest performance panel, the High-diversity SNP microhaple
conducted to assess its utility in capturing key populat Further evaluated to assess its utility in capturing key population genetic features. The genetic diversity of the H
diversity SNP panel was assessed for isolates from each of the 7 geographic regions using measures of
het diversity SNP panel was assessed for isolates from each of the 7 geographic regions using measures of
heterozygosity and effective cardinality. Heterozygosities across the microhaplotypes varied, but overall dive
was high diversity STM panel was assessed for the Care of the Termin Care of the Termin and STM parameters in the terozygosity and effective cardinality. Heterozygosities across the microhaplotypes varied, but overa was high in all heterozygosity and effective cardinality. Heterozygositives across the micrology was high in all geographic regions (median > 0.70, i.e., >70% chance on average that two randomly selected
isolates will differ at a marker) was high in all differ at a marker) (**Table 3, Figure 3a**). The lowest diversity was observed in the horn of Africa
(median heterozygosity = 0.70) and the highest in Oceania (median heterozygosity = 0.81). Similar trends
o isolates will differ at a marker) (Table 3, Figure 3a). The lowest diversity was observed in the horn of Africa
(median heterozygosity = 0.70) and the highest in Oceania (median heterozygosity = 0.81). Similar trends
occur occurred in effective cardinality (roughly equivalent to the number of alleles, with adjustment for minor a
frequency), with median values ranging from 3.88 in Africa to 5.18 in Oceania (**Table 3, Figure 3b**). The hige
eff frequency), with median values ranging from 3.88 in Africa to 5.18 in Oceania (**Table 3, Figure 3b**). The highest
effective cardinality observed in the data set was a microhaplotype with a score of 36.9 (roughly 36 differ requency), with median values ranging from 3.88 in Africa to 3.18 in Oceania (Table 3, Figure 3b). The highest
effective cardinality observed in the data set was a microhaplotype with a score of 36.9 (roughly 36 different
 alleles at a single microhaplotype marker) in West Southeast Asia (**Table 4**). A list of the microhaplotypes amouthe top three most diverse markers in each region is presented in Supplementary Table 2. Microhaplotype PvP01 alleles at a single intervial protype marker) in west Southeast Asia (Table 4). A list of the intervial protypes amongst
the top three most diverse markers in each region is presented in Supplementary Table 2. Microhaplot

the top top three matters manufal methods presented in experimentally that a mongst the 3 most diverse markers in all 7 regions.

Within-host diversity estimates using the High-diversity SNP microhaplotype panel were gener Purpose markers in all 7 regions.

Within-host diversity estimates using the High-diversity SNP microhaplotype panel were generated for each

isolate using Complexity of Infection (COI) measures and correlated with the ge Within-host diversity estimates
isolate using Complexity of Infection
from the F_{WS} score. Using thresh
significant differences in the pro
data in any geographic region (**T**
with COI=1 was significantly larg ハ i f c () isolate using Complexity of Infection (COI) measures and correlated with the genome-wide estimates derived
from the F_{WS} score. Using thresholds of COI = 1 and $F_{\text{WS}} \ge 0.95$ to define a monoclonal infection, there From the F_{WS} score. Using thresholds of COI = 1 and $F_{WS} \ge 0.95$ to define a monoclonal infection, there were no
significant differences in the proportion of polyclonal infections defined by the microhaplotype and gen from the FWS score. Using thresholds of COI = 1 and FWS ≥ 0.95 to define a monoclonal infection, there were no
significant differences in the proportion of polyclonal infections defined by the microhaplotype and genome-wi
 Shall are in any geographic region (**Table 4**). Furthermore, as illustrated in **Figure 4**, the F_{WS} scores of the infections with COI=1 was significantly larger than those with COI>1 in all regions, demonstrating a s

data in any geographic region (Table 4). Furthermore, as indicated in Figure 4, the FWS secrets of the infections
with COI=1 was significantly larger than those with COI>1 in all regions, demonstrating a strong alignment
 where the microhaplotype and genomic data (**Table 4**).
The capacity of the High-diversity SNP microhaplotype panel to capture spatial transmission patterns inclu
differentiation of geographically distinct populations was a between the interomaplotype and genomic data (Table 4).
The capacity of the High-diversity SNP microhaplotype pan
differentiation of geographically distinct populations was a
(PCoA) and IBD-based networks. The microhaploty The capacity of the Higheral of the Higheral Conditions (PCOA) and IBD-based networks. The microhaplotype-based PCOA trends were consistent with spatial trends observed with genome-wide datasets²⁰. Analysis of all the av (PCoA) and IBD-based networks. The microhaplotype-based PCoA trends were consistent with spatial trend
observed with genome-wide datasets²⁰. Analysis of all the available *P. vivax* data demonstrated three major
clusters (PECO) and IRCO and Benome-wide datasets²⁰. Analysis of all the available *P. vivax* data demonstrated three major
clusters with PC1 and PC2 representing South America, Africa and West Asia (group 1), East and West South observed with genome-wide datasets²⁰. Analysis of all the available *P. vivax* data demonstrated three major
clusters with PC1 and PC2 representing South America, Africa and West Asia (group 1), East and West South
Asia Asia (group 2), and Oceania and Maritime Southeast Asia (group 3) (**Figure 5a**). Clear differentiation of the regional groups was observed within each of the major clusters. To retain accuracy in MAF estimates, IBD-based Asia (group 2), and oceania and Maritime Southeast Asia (group 3) (Figure 3a). Clear differentiation of the regional groups was observed within each of the major clusters. To retain accuracy in MAF estimates, IBD-lanalyse analyses were restricted to within each of the 7 regional groupings. In all geographic regions, the microhaplotype
based estimates of pairwise IBD demonstrated a significant positive correlation with the genome-wide estima based estimates of pairwise IBD demonstrated a significant positive correlation with the genome-wide estimates

(all $P<0.05$, **Supplementary Figure 3**). In Maritime Southeast Asia, a major clonal outbreak in Malaysia (de (all P<0.05, **Supplementary Figure 3**). In Maritime Southeast Asia, a major clonal outbreak in Malaysia (defined K2) that we have described previously with genomic data²⁷, was also distinguished clearly with the microha (all Psolos), supplementary Figure 3). In Maritime Southeast Asia, a major cional outbreak in Malaysia (defined
K2) that we have described previously with genomic data²⁷, was also distinguished clearly with the
microhap K2) that we have described previously with genomic data²⁷, was also distinguished clearly with the microhaplotypes (Figure 5b). Furthermore, more subtle sub-structure, including the resolution of p
defined K3 and K4 Mala microhaplotypes (Figure 5b). Furthermore, more sub-structure, including the resolution of previously
defined K3 and K4 Malaysian sub-populations was also captured with the microhaplotypes. In other geograp
6 α and K3 and K4 Malaysian subsections was also captured with the microhaplot α

regions, patterns of infection relatedness were largely consistent with genomic patterns described in previous
studies (**Supplementary Figure 4**)²⁰. The largest infection networks were observed in South America and Papu studies (**Supplementary Figure 4**)²⁰. The largest infection networks were observed in South America and Papua
New Guinea. Small networks were observed in other regions, but most infections were unrelated at a minimal l
t

threshold of 0.25 (consistent with half-siblings or closer). In East Southeast Asia, cross-border networks were
observed between Thailand and Vietnam.
Further spatial evaluations of the High-diversity SNP microhaplotype pa observed between Thailand and Vietnam.

Further spatial evaluations of the High-diversity SNP microhaplotype panel were undertaken to assess the

accuracy of the panel in detecting imported P. vivax cases by determining an Further spatial evaluations of the High-divention
accuracy of the panel in detecting importe
the data from 21 countries with a minimur
determined the accuracy of the 494 SNPs v
recently developed Bi-Allele Likelihood (BA
S ー・・・ しょうしょう accuracy of the panel in detecting imported *P. vivax* cases by determining an infection's country of origin. I
the data from 21 countries with a minimum sample size of 4 from the available *P. vivax* global dataset, we
d accuracy of the panel in detecting imported P. vivax cases by determining an infection's country of origin. Osing
the data from 21 countries with a minimum sample size of 4 from the available P. vivax global dataset, we
de the data from 21 counties with a minimum sample size of 4 from the available P. *Wook* global dataset, we
determined the accuracy of the 494 SNPs within the microhaplotype panel in predicting country of origin t
recently d determined the accuracy of the accuracy of the 494 microhaplotype
sNPs was compared to the 38-SNP Broad barcode and three recently identified P. vivox geographic barcodes
selected specifically for determining country of or recently developed Bi-Allele Likelihood (BALK) classifier²⁶. The predictive accuracy of the 494 microhaplotype
SNPs was compared to the 38-SNP Broad barcode and three recently identified *P. vivax* geographic barcodes
se SNPS was compared to the 38–SNP Broad barcode and three recently identified P. *Vivax* geographic barcodes selected specifically for determining country of origin (GEO33, GEO50 and GEO55 comprising 33, 50 and 55 SI respect selectively²⁸. The median Matthew's correlation coefficient (MCC, ranging from -1 when prediction is 0% correct to 1 when prediction is 100% correct) of the 494 microhaplotype SNPs were greater than or equal to the 38-SN respectively)²⁸. The median Matthew's correlation coefficient (MCC, ranging from -1 when prediction is 0% correct to 1 when prediction is 100% correct) of the 494 microhaplotype SNPs were greater than or equal to 38-SNP 38-SNP Broad barcode, GEO33 and GEO50 in 21 (100%) countries (**Table 5, Figure 6**). The GEO55 panel exhibited
higher MCCs than the microhaplotype panel in 3/21 (14%) countries (Cambodia, Indonesia and Vietnam) but
lower va 38 3NY Broad barcode, GEO33 and GEO30 in 21 (100%) countries (Table 3, Figure 9). The GEO33 panel exhibited higher MCCs than the microhaplotype panel in 3/21 (14%) countries (Cambodia, Indonesia and Vietnam) but lower valu hower values in 4/21 (19%) countries (Afghanistan, India, Myanmar and Thailand). The median MCCs of the
microhaplotype panel exceeded 0.9 in all countries except Cambodia and Vietnam (19/21, 90%); the median
MCCs in these microhaplotype panel exceeded 0.9 in all countries except Cambodia and Vietnam (19/21, 90%); the median
MCCs in these countries were also <0.9 at the 38-SNP Broad barcode and the three GEO panels.
Discussion
Our study prov

Discussion

MCCs in these countries were also <0.9 at the 38-SNP Broad barcode and the three GEO panels.

Discussion

Our study provides the first description in silico of *P. vivax* microhaplotype panels which can be used to estim

" **Discussion**
Our study provides the first description in silico of *P. vivax* microhaplotype panels which can be t
"identity by descent" relatedness between pairs of acute and recurrent infection isolates, and th
discrimi Our study provides the first description in since of P. Vivax interonaptotype panels which can be used to estimate
"identity by descent" relatedness between pairs of acute and recurrent infection isolates, and thus help to The immum of the between different causes of vivax malaria recurrence. A systematic genome-wide selection provas used to identify panels of 100 globally diverse microhaplotypes using an expansive *P. vivax* genome da
The u discriming was used to identify panels of 100 globally diverse microhaplotypes using an expansive P. vivax genome dataset.
The utility of these panels was assessed against a pre-existing P. vivax SNP panel using both simul was used to identify panels of 100 globally diverse internalplotypes dailig an expansive P. *Wiva* genome dataset.
The utility of these panels was assessed against a pre-existing *P. vivax* SNP panel using both simulated a The utility of these panels was assessed against a pre-existing P. Vivia SNP panel using both simulated and whole
genome data. These relatively parsimonious panels have significant potential to improve the interpretation o

genome data. Further details on the integration of microhaplotype data in the proposed using a cases, and areas requiring further research and development are described herein.
A key requirement of the *P. vivax* microhapl cases, and areas requiring further research and development are described herein.

A key requirement of the *P. vivox* microhaplotype panels was the ability to estimate IBD accurately between

paired isolates and thereby h cases, and areas requirement of the *P. vivax* microhaplotype panels was the ability to estimate paired isolates and thereby help to classify the likely origin of vivax malaria recurrer recrudescence or reinfection) in cli r
II
N
N A key requirement of the P. vivax interonaplotype panels was the abinty to estimate IBD accurately between
paired isolates and thereby help to classify the likely origin of vivax malaria recurrence (i.e., relapse,
recrudes pair examples and the microhaplotype pane
econsistently higher accuracy in IBD estimation (across different IBD levels and in different population
42-SNP Broad barcode that is currently the most widely used SNP barcode for recrudescence or refugees and indifferent productions) than the 42-SNP Broad barcode that is currently the most widely used SNP barcode for *P. vivax*. This is not surprising as microhaplotypes have substantially greater g 22-SNP Broad barcode that is currently the most widely used SNP barcode for *P. vivax*. This is not surprising as the microhaplotypes have substantially greater genetic information content compared with the 38 evaluable Br 42 SNP Broad barcode that is currently the most wherey dised SNP barcode for P. vivax. This is not surprising as the microhaplotypes have substantially greater genetic information content compared with the 38 evaluable Bro SNPs. We also demonstrated greater efficacy of IBD estimation when microhaplotypes were selected to meet
specified diversity criteria (High-diversity SNP panel) relative to microhaplotypes with random SNP selections
(anyspecified diversity criteria (High-diversity SNP panel) relative to microhaplotypes with random SNP selections (any-SNP panel). In accordance with previous predictions¹⁸, our simulation-based results demonstrated error specified diversity and the estimation of pairwise IBD in all populations tested using the high-diversity microhaplotype panel. The error rates were highest for the prediction of infections with 50% IBD. Further work meed (any-SNP panel). In accordance with previous predictions²⁸, our simulation-based results demonstrated error
rates below 12% in the estimation of pairwise IBD in all populations tested using the high-diversity
microhaplo microhaplotype panel. The error rates were highest for the prediction of infections with 50% IBD. F
needed to understand how this might impact clinical predictions of individual treatment response of
level drug efficacy bo meeded to understand how this might impact clinical predictions of individual treatment response or population-
level drug efficacy both in the context of descriptive data analyses and mathematical models²⁹. In descripti nevel drug efficacy both in the context of descriptive data analyses and mathematical models²⁹. In descriptive

T level drug efficacy both in the context of descriptive data analyses and mathematical models29. In descriptive

relatedness values greater than 25% are suggestive of relapse) are used to classify recurrences categorically.
Rules-based classification is not the same as estimating the probability of relapse given the data under a
stat relatedness values greater than 25% are suggestive of relapse) are used to classify recurrences categorically.
Rules-based classification is not the same as estimating the probability of relapse given the data under a
sta statistical model (as in Taylor et al²⁹, which also accounts for the added complexity associated with multi-
infections). Nevertheless, improved data informativeness for IBD estimation likely translates into improv
model statistical model (as in Taylor et al²², which also accounts for the added complexity associated with multiclonal
infections). Nevertheless, improved data informativeness for IBD estimation likely translates into improve model-based probabilistic classification performance, at least in the case of the model of Taylor, because th
model machinery includes an intermediary that evaluates the probability of the data given IBD partitions
compati

model machinery includes an intermediary that evaluates the probability of the data given IBD partitions
compatible with networks of sibling, clonal and stranger parasites²⁹.
It should be acknowledged that panel evaluati compatible with networks of sibling, clonal and stranger parasites²⁹.
It should be acknowledged that panel evaluation based on simulated data was done in a highly idealised r
that captures panel performance in its most f compatible with networks of sibling, clonal and stranger parasites".
It should be acknowledged that panel evaluation based on simulated
that captures panel performance in its most favourable light. Data w
estimate relatedn | t c
c c c c i It is a capture and performance in its most favourable light. Data were simulated under the same model used to
estimate relatedness, such that the model was perfectly specified in relation to the simulated data. Real data that capture performance in that the model was perfectly specified in relation to the simulated data. Real data are
generated by an ancestral process that the model does not capture, i.e., the model is miss-specified in re estimated by an ancestral process that the model does not capture, i.e., the model is miss-specified in relation to
real data. The impact of miss-specified allele frequencies, miss-classified multiclonal infections, etc. w generated by an ancestral presentation process that the model of productions, the model data. The impact of miss-specified allele frequencies, miss-classified multiclonal infections, etc. was not evaluated. In addition, it real uated. In addition, it should be acknowledged that genotyping errors and failures (missing data) were no
included in our simulations. However, we anticipate that genotyping failures should be infrequent with NGS-
base

included in our simulations. However, we anticipate that genotyping failures should be infrequent with NGS-
based amplicon sequencing methods, where each locus is typically covered by hundreds of reads¹⁹.
Data from pairs based amplicon sequencing methods, where each locus is typically covered by hundreds of reads¹⁹.
Data from pairs of *P. vivox* isolates, collected from recurrent infections in clinical trials, confirmed the ability
the h based amplicon sequencing methods, where each locus is typically covered by hundreds of reads²⁵.
Data from pairs of *P. vivax* isolates, collected from recurrent infections in clinical trials, confirmed th
the high diver Itrkre Data from pairs of P. vivax isolates, conceted from recurrent infections in einical trials, commined the ability of
the high diversity microhaplotype panel to estimate pairwise IBD. High correlations were observed between
 microhaplotype and genome wide IBD estimates in a set of 14 paired *P. vivax* isolates from the same patient
before and after treatment. Using our assigned IBD thresholds, only one of 14 pairs of infections had
mismatching micronaplotype and genome wide IBD estimates in a set of 14 paired P. Wivia Isolates from the same patient
before and after treatment. Using our assigned IBD thresholds, only one of 14 pairs of infections had
mismatching c mismatching classifications of 'stranger' versus 'distant relative', which are both likely to reflect either
reinfections or relapses. However, the available genomic data did not comprise any infection pairs wit
estimates minimitions or relapses. However, the available genomic data did not comprise any infection pairs with
estimates around 50% (i.e., siblings), which our simulations predicted to be the most difficult relationsl
determine ac refinance around 50% (i.e., siblings), which our simulations predicted to be the most difficult relationships t
determine accurately. The number of genomic pairs was limited owing to the difficulty in obtaining enough
and estimates around 50%. The number of genomic pairs was limited owing to the difficulty in obtaining enough D
and thus high-quality sequence data from recurrent infections, which typically exhibit low parasite densities.
Is and thus high-quality sequence data from recurrent infections, which typically exhibit low parasite densities. This
is a major incentive for using targeted genotyping approaches. Nonetheless, we demonstrated high correlati and thus higher the microhaplotype and genotyping approaches. Nonetheless, we demonstrated high correlations
between the microhaplotype and genome wide IBD estimates in the assessments of day 0 samples, where a
range of IB

is a major increment for a major ingular genotyping approaches in the assessments of day 0 samples, where a
range of IBD relationships were observed.
In some scenarios, genetic data alone will not be informative of the lik Frange of IBD relationships were observed.

In some scenarios, genetic data alone will not be informative of the likely origin of a recurrence. A single

mosquito inoculation may carry clonal parasites or related parasites In some scenarios, genetic data alone will
mosquito inoculation may carry clonal para
heterologous clones. If a human host carric
therefore either be homologous or related
relapses are homologous, they will be gene
hypnozo mosquito inoculation may carry clonal parasites or related parasites generated through recombination of
heterologous clones. If a human host carries hypnozoites from a single inoculation, the relapsing parasite
therefore e heterologous clones. If a human host carries hypnozoites from a single inoculation, the relapsing parasites
therefore either be homologous or related (meiotic siblings) to the incident infection. In situations where
relaps therefore either be homologous or related (meiotic siblings) to the incident infection. In situations where the
relapses are homologous, they will be genetically indistinguishable from recrudescence. If a host carries
hypn relapses are homologous, they will be genetically indistinguishable from recrudescence. If a host carries
hypnozoites from one or more previous mosquito inoculations, relapsing parasites are liable to be
unrelated/heterolo relapsing parasites are liable to be
unrelated/heterologous to the incident infection, and thus genetically indistinguishable from reinfection
study, a high proportion of infection pairs (79%) had homologous genomes, altho melated/heterologous to the incident infection, and thus genetically indistinguishable from reinfe
study, a high proportion of infection pairs (79%) had homologous genomes, although the majority
derived from low seasonal t unrelated, a high proportion of infection pairs (79%) had homologous genomes, although the majority (86%) of pairs
derived from low seasonal transmission settings in Malaysian Borneo, southern Vietnam, Cambodia and western starty, a high proportion pairs pairs (79%) had hold pairs (79%) and homeo, southern Vietnam, Cambodia and western
Thailand. A therapeutic efficacy study undertaken in Peru also identified a moderately high proportion of
g Thailand. A therapeutic efficacy study undertaken in Peru also identified a moderately high proportion of genetically homologous recurrences $(52\%, 12/23)^{12}$. The proportion of relapses amongst the recurrences in our an genetically homologous recurrences $(52\%, 12/23)^{12}$. The proportion of relapses amongst the recurrences is
and the Peruvian study is uncertain. In a therapeutic efficacy study undertaken in Cambodia, 20 patients v
reloc genetically homologous recurrences (52%, 12/23)¹². The proportion of relapses amongst the recurrences in our
and the Peruvian study is uncertain. In a therapeutic efficacy study undertaken in Cambodia, 20 patients were
r relocated to a malaria-free area excluding the possibility of reinfection; the authors were able to define
confidently 5 recurrences as relapses and demonstrated that 4 (80%) of these were related to the initial
8 confidently 5 recurrences as relapses and demonstrated that 4 (80%) of these were related to the initial $\frac{8}{100}$ confidently 5 recurrences as related that 4 (40%) of the initial 4 (40%) of the init

infection³⁰. As more comprehensive data become available, a clearer picture of the epidemiology of recurrent *P.*
vivax infections will emerge. Even in areas where the prevalence of related recurrences is low, mathematic

vivax infections will emerge. Even in areas where the prevalence of related recurrences is low, mathematical
modelling approaches that combine genetic data with time-to-event data will help to resolve the probable ca
of re modelling approaches that comprehensive understanding that comprehensive understanding of
Another key requirement of the microhaplotype panel was the ability to capture spatial *P. vivax* transmission
dynamics. Strategies of recurrence".
Another key req
dynamics. Strate
the major routes
panel displayed
detecting and m
intentionally sele ノ c t ド c i r Another key requirement of the microhaplotype panel was the ability to capture spatial P. *Vivax* transmission
dynamics. Strategies to contain P. *vivax* effectively will be assisted by a more comprehensive understanding o dynamics. Strategies to contain P. Vivax effectively will be assisted by a more complementare understanding of
the major routes of infection spread within and across borders. The SNP-based data from our microhaplotype
pane the majority of origin, suggesting utility
panel displayed clear geographic trends and high accuracy in predicting the country of origin, suggesting utility
detecting and mapping imported P. vivax cases. Although the highparel in graphic trends and mapping imported *P. vivax* cases. Although the high-diversity microhaplotype panel was not intentionally selected for country prediction, we captured 494 high diversity bi-allelic SNPs with 100 detecting and mapping imported P. vivax cases. Although the high-diversity interonaplotype panel was not
intentionally selected for country prediction, we captured 494 high diversity bi-allelic SNPs with 100
microhaplotype interior and these highly informative genetic data enabled high performance country predictionally prediction
compared to recently described geographic marker panels (GEO33, GEO50 and GEO55) that were se
specifically to di man entropies per antiveles highly interacted geographic marker panels (GEO33, GEO50 and GEO55) that were selected
specifically to differentiate P. vivax populations by country²⁸. The accuracy in pairwise IBD estimation example to differentiate P. vivax populations by country²⁸. The accuracy in pairwise IBD estimation using
microhaplotype data also demonstrates a unique potential for tracking infection spread at micro-epidemio
spatial r specifically to differentiate P. vivax populations by country²⁶. The accuracy in pairwise IBD estimation using the
microhaplotype data also demonstrates a unique potential for tracking infection spread at micro-epidemiol microhaplotype data from the dispersal of infections within and between communities. For example, the
microhaplotype data from Malaysia effectively captured a previously described clonal expansion, as well as more
subtle p incrohaplotype data from Malaysia effectively captured a previously described clonal expansion, as well as
subtle population structure reflecting different foci of infection. The spatial analyses conducted here used k
SNP subtle population structure reflecting different foci of infection. The spatial analyses conducted here used biallelic
SNP data at the microhaplotypes; whilst the high density of SNPs (n=494) provided rich genetic informat SNP data at the microhaplotypes; whilst the high density of SNPs (n=494) provided rich genetic information, even
greater information content can be achieved using multiallelic microhaplotypes once new software to deal wit

STREAT INTERT AT A BET A THE MINOT CONTROLLED THE MINOT ARE COMPLEX AT A THE MINOT ARE COMPLEX datasets becomes available.
Some global regions are not well represented in the Pv4 genomic dataset that were used for marker s greate complex datasets becomes available.
Some global regions are not well represented in the Pv4 genomic dataset that were used for marker selection,
such as the Indian subcontinent, Central and South America. It is ther Some global regions are not well represente
such as the Indian subcontinent, Central and
described here will capture IBD in these reg
microhaplotype selection can be applied rea
data become available from new geographic
sp cicles in the search of the controller of the controller of the controller of the controller of the controller
Controller of the controller of the co Such as the Indian subcontinent, Central and South America. It is therefore unclear how well the microhaplotyp
described here will capture IBD in these regions. However, the informatics pipeline that was established for th such a the Indian subcontinent, the Indian South America. In the Indian subcontinent is the Indian subcontinent
described here will capture IBD in these regions. However, the informatics pipeline that was established for t microhaplotype selection can be applied readily to update the panel as needed once additional whole genome
data become available from new geographical regions. The pipeline can also be used to select country- or region
sp

microhaplotype selection can be applied readily to update the panel as needed once additional whole genome
data become available from new geographical regions. The pipeline can also be used to select country- or region-
s data become available from new geographical regions. The pipeline can also be used to select country \sim regions specific panels where needed.

Information on within-host infection complexity is important to capture epid Information on within-host inference
dynamics. We observed high co
based COI and genome-wide F_1
infections displayed difference
datasets. In interpreting these
guideline, and that population dynamics. We observed high concordance in the proportion of polyclonal infections captured by microhaplotype
based COI and genome-wide F_{Ws} measures when thresholds of COI=1 and F_{WS} 20.95 were applied. Only a f dynamics. We observe the proportion of polyclonal infections displayed COI and genome-wide F_{Ws} measures when thresholds of COI=1 and $F_{\text{WS}} \ge 0.95$ were applied. Only a few of infections displayed differences in c based COI and genome wide *FWS* measures when thresholds of COI=1 and *FWS* 20.95 were applied. Only a few of
infections displayed differences in classification of polyclonality between the microhaplotype and genomic
datas datasets. In interpreting these differences, it should be acknowledged that the 0.95 F_{WS} threshold is only a guideline, and that population distributions of within-host diversity generally reflect a continuum, not d

datasets. In interpreting these differences, it should be acknowledged that the 0.95 FWS threshold is only a
guideline, and that population distributions of within-host diversity generally reflect a continuum, not discr
cl guideline, and that populations.
Within-host diversity at SNP barcodes also follows a continuum, but this is less marked owing to the lower gene
resolution. When monoclonal thresholds were only applied to the COI data, the Within-host diversity at SNP barcodes also follow
resolution. When monoclonal thresholds were on
larger values in the COI=1 (monoclonal) vs COI>1
investigated, highlighting consistency between th
phase microhaplotype profi resolution. When monoclonal thresholds were only applied to the COI data, the F_{WS} demonstrated significantly
larger values in the COI=1 (monoclonal) vs COI>1 (polyclonal) infection group in all geographic regions
in resolution. When monoclonal thresholds were only applied to the COI data, the F_{WS} demonstrated significantly
larger values in the COI=1 (monoclonal) vs COI>1 (polyclonal) infection group in all geographic regions
investi larger investigated, highlighting consistency between the two data sets. Further work is needed to determin
phase microhaplotype profiles in highly complex infections where any number of clones may be present
varying propo inversigated, highlighting consistency is complex infections where any number of clones may be present in
parying proportions, but tools such as the *Dcifer* software provide an important step forward³¹. Indeed, phasing
 phase microhaplotype promission, supplementation intervals, manufacture complete intervals in protice in the provides and important step forward³¹. Indeed, phapolyclonal malaria infections is not a challenge unique to mi varying proportions, but tools such as the *Dcifer* software provide an important step forward³². Indeed, phasing of
polyclonal malaria infections is not a challenge unique to microhaplotypes.
9 $p = \frac{1}{2}$

The P. vivax genome has an abundance of globally diverse interomaplotype regions that can encerty capture
Information on infection lineages and spatial connectivity, overcoming the previous requirement to generate
genomic genomic data in samples that are often notoriously difficult to sequence. With targeted, deep sequencing
platforms, these markers have great potential to inform on the complex diversity within individual infections
associa genomic platforms, these markers have great potential to inform on the complex diversity within individual infection
associated insights on transmission. The establishment of targeted microhaplotype genotyping tools for P. plassociated insights on transmission. The establishment of targeted microhaplotype genotyping tools for *P. vivax*
will transform the assessment of clinical surveys in this species, enhance knowledge of relapse biology, a associated insights on transmission. The establishment of targeted microhaplotype genotyping tools for P. vivax
will transform the assessment of clinical surveys in this species, enhance knowledge of relapse biology, and
g greatly improve surveillance of infections.
Methods
Data preparation
The initial dataset comprised 1,816 samples from 17 countries derived from the *P. vivax* community study (I

Methods

Data preparation

greatly
**Methods
Data preparation
The initial dataset comprised 1,816 sample
in the vivax and Malaria Genomic Epidemie** The initial dataset comprised 1,016 samples from 17 countries derived from the P. Vivax community study (Pv4.0)
in the vivax and Malaria Genomic Epidemiology Networks (vivaxGEN and MalariaGEN)²⁰, as well as previously
p in the vivax and Malaria Genomic Epidemiology Networks (vivaxGEN and MalariaGEN)²⁰, as well as previously published external studies³²⁻³⁴. Of the 1,895 samples described in Pv4.0 data note, the 1,816 samples reflect d published external studies²²²³. Of the 1,895 samples described in Pv4.0 data note, the 1,816 samples reflect data
for which we had access prior to the open release. All genomic datasets were generated using Illumina sh sequencing platforms. Sequence alignment, SNP discovery and variant calling, population assignments, and Fws
(within-sample F statistic) calculations for within-host allele infection complexity were undertaken using
previ sequencing platforms. Sequence alignment, SNP discovery and variant calling, population assignments, and Fws
(within-sample F statistic) calculations for within-host allele infection complexity were undertaken using
previ previously described methods within the MalariaGEN framework, producing a dataset referred to as *P.* v.
Genome Variation Project release 4.0 (Pv4.0). The F_{ws} estimates the fixation of alleles within each infective previously described methods within the MalariaGEN framework, producing a dataset referred to as P. vivax
Genome Variation Project release 4.0 (Pv4.0). The F_{WS} estimates the fixation of alleles within each infection
rel Genome variation Project release 4.0 (Pv4.0). The F_{WS} estimates the fixation of alleles within each infection
relative to the diversity observed in the total population on a scale from 0 to 1 and were provided as part of Pv4 dataset^{20,35}. Using a threshold of $F_{WS} \ge 0.95$ as a proxy to identify a monoclonal infection, all polyclonal
infections were excluded from subsequent analysis. High-quality samples were selected using a threshold Pv4 dataset^{20,35}. Using a threshold of $F_{WS} \ge 0.95$ as a proxy to identify a monoclonal infection, all polyclonal
infections were excluded from subsequent analysis. High-quality samples were selected using a threshold
 infections were excluded by the "analysis-set" flag in the MalariaGEN Pv4 dataset. The patient metadata provided by
the contributing VivaxGEN partner studies was used to identify independent isolates for marker selection, the contributing VivaxGEN partner studies was used to identify independent isolates for marker selection, and
recurrent isolates for downstream evaluation of selected marker sites. The MalariaGEN curated metadata was
used recurrent isolates for downstream evaluation of selected marker sites. The MalariaGEN curated metadata was
used to define 7 regional-level geographic assignments with the following categories: Africa (AF), South and
Centra used to define 7 regional-level geographic assignments with the following categories: Africa (AF), South and
Central America (SAM), West Southeast Asia (WSEA), East Southeast Asia (ESEA), Maritime Southeast Asia
(MSEA), Oc Central America (SAM), West Southeast Asia (WSEA), East Southeast Asia (ESEA), Maritime Southeast Asia
(MSEA), Oceania (OCE) and West Asia (WAS). The regional classifications were based on genomic clustering
patterns in th (MSEA), Oceania (OCE) and West Asia (WAS). The regional classifications were based on genomic clustering
patterns in the Pv4.0 data notated as "analysis population" flag.
Marker selection
We tailored our marker selectio

Marker selection

patterns in the Pv4.0 data notated as "analysis population" flag.

Marker selection

We tailored our marker selection to the Illumina amplicon-based sequencing workflow as this methodology

widely used in the malaria comm part of the Pv4.0 data notation

We tailored our marker selection to the Illumina amplicon-based

widely used in the malaria community and has demonstrated uti

surveillance in low- and middle-income countries¹⁷. The max - ハード こうしょう widely used in the malaria community and has demonstrated utility and feasibility for malaria molecular
surveillance in low- and middle-income countries¹⁷. The maximum amplicon size for Illumina amplicon-based
sequencin where in low-and middle-income countries¹⁷. The maximum amplicon size for Illumina amplicon-basequencing is 200 bp, which set the criteria for the maximum length of each microhaplotype. The target is of microhaplotypes w surveillance in low- and middle-income countries²⁷. The maximum amplicon size for Illumina amplicon-based
sequencing is 200 bp, which set the criteria for the maximum length of each microhaplotype. The target num
of micr of microhaplotypes was set to 100 based on a mathematical modelling study, which demonstrated that under
idealised settings (i.e., estimating relatedness from data simulated under the model used for estimation), IBD
estima idealised settings (i.e., estimating relatedness from data simulated under the model used for estimation), IBD
estimates with low root mean squared error (RMSE<0.1) between monoclonal malaria parasites with relatedne
equal estimates with low root mean squared error (RMSE<0.1) between monoclonal malaria parasites with relatedney equal to 0.5 (relatedness with the highest RMSE) are obtainable using ~100 polyallelic markers¹⁸. Diminishing ret equal to 0.5 (relatedness with the highest RMSE) are obtainable using ~100 polyallelic markers¹⁸. Diminishing
returns in RMSE reduction were observed above 100 polyallelic markers, highlighting this target number as a
pr equal to 0.5 (relatedness with the highest RMSE) are obtainable using ~100 polyallelic markers*". Diminishing
returns in RMSE reduction were observed above 100 polyallelic markers, highlighting this target number as a
prag returns in MMSE relation were subserved above 100 primers in programs. Panels of microhaplotypes (schemes pragmatic balance of IBD accuracy against the economic cost of primers¹⁸. Panels of microhaplotypes (schemes Figur pragmatic balance of IBD accuracy against the economic cost of primers³⁶. Panels of microhaplotypes (schematic
Figure 1a) were subsequently selected to optimise marker selection with the previously identified criteria us Figure 1a) were subsequently selected to optimise marker selection with the previously identified criteria using a

three phase approach as described in Figure 1b with respect to sample, variant and window selection. In the first
phase, samples were subset from the MalariaGEN Pv4.0 dataset that consisted of high-quality samples as
ident identified in Pv4 as being independent, 50% of the genome callable, and likely monoclonal with Fws ≥0.95
second phase, candidate SNPs were identified by filtering the high-quality biallelic SNPs (filter pass), with i
alle identified in FV4 as being independent, 50% of the genome canable, and likely indioderation with Fws 20.95. In the
second phase, candidate SNPs were identified by filtering the high-quality biallelic SNPs (filter pass), wi allele frequency (MAF) <0.1 and genotype failure rates >0.1. Finally, candidate microhaplotype windows were identified by scanning the core genome (excluding hypervariable regions) in coding regions with 50 bp overlapping, identified by scanning the core genome (excluding hypervariable regions) in coding regions with 50 bp
overlapping, 200 bp windows to identify amplicon-sized segments containing at least one candidate SNP,
producing what we overlapping, 200 bp windows to identify amplicon-sized segments containing at least one candidate SN
producing what we define as the heterozygome map of the accessible regions of the *P. vivax* genome (
Once the windows we producing what we define as the heterozygome map of the accessible regions of the *P. vivax* genome (**Fig**
Once the windows were identified, they were further filtered to a minimum heterozygosity of 0.5 for a tot
5,460 win producing what we define as the heterozygome map of the accessible regions of the P. vivax genome (Figure 1c).
Once the windows were identified, they were further filtered to a minimum heterozygosity of 0.5 for a total of
 5,460 windows. Panels of 100 microhaplotypes were then selected from the *P. vivax* heterozygome by selecting
only windows that had between 3-10 SNPs, and approximately evenly distanced spacing across 14 chromosome
The "Ra 5,460 windows. Panels of 100 microhaplotypes were then selected from the P. *Vivax* heterozygome by selecting
only windows that had between 3-10 SNPs, and approximately evenly distanced spacing across 14 chromosome:
The "R only "marked" many space and 100 markers chosen irrespectively of diversity (with a minimum of 0.5
The "Random mhaps" panel had 100 markers chosen irrespectively of diversity (with a minimum of 0.5
heterozygosity in a give The "Random mapper panel manufacture in the "Random methods" panel had each of its markers chosen with the highest possible
heterozygosity in a given genomic region (Figure 1d). Measures of MAF and heterozygosity were calc heterozygosity in a given genomic region (Figure 1d). Measures of MAF and heterozygosity were calcula
the scikitallel package.
Population genetic evaluation of the microhaplotype panel
To evaluate the efficacy of the sel

Population genetic evaluation of the microhaplotype panel

heterozygosity in a given genomic region (Figure 1d). Measures of MAF and heterozygosity were calculated using
the scikitallel package.
To evaluate the efficacy of the selected microhaplotype panel
To evaluate the efficacy Population genetic evolution
To evaluate the efficacy
barcode, population diverses
geographic regions usin $\frac{1}{\epsilon}$ To evaluate the efficacy of the selected intronapplotype panel relative to the Broad P. *Vivax* barcode as a global
barcode, population diversity was assessed at each panel (microhaplotype and Broad) for each of the 7
geog barcode, population diversity intertional teach pairs (microspyre), points at the R-based geographic regions using measures of effective cardinality and heterozygosity computed with the R-based panel judge package (https: geonelization and paralistics.//github.com/aimeertaylor/panelizaties). Analyses were conducted on the highmonoclonal samples using one of the two alleles selected at random to reconstruct microhaplotypes at heterozygote ge paneljudge package (<u>https://github.com/aimeertaylor</u>/paneljudge). Analyses were conducted on the high–quality
monoclonal samples using one of the two alleles selected at random to reconstruct microhaplotypes at
heterozygo heterozygote genotype positions using the "haploidify" function in Scikit-allel. Measures of within-host were also generated using *THE REAL McCOIL* package on the biallelic SNPs in the High-diversity microhaplanel and co

were also generated using *THE REAL McCOIL* package on the biallelic SNPs in the High-diversity microhaplotype
panel and correlated against the genome-wide F_{WS} estimates of infection complexity^{35,36}.
The potential of were also generated using THE REAL McCOIL package on the bialient SNP sin the High-diversity incronaplotype
panel and correlated against the genome-wide F_{WS} estimates of infection complexity^{35,36}.
The potential of panel and correlated against the genome-wide F_{WS} estimates of infection complexity^{99,36}.
The potential of the biallelic SNPs within the microhaplotype panel in capturing spatial pa
was assessed using Principal Coo - \
| | |
| | The positions assessed using Principal Coordinate Analysis (PCoA) to illustrate the regional level geographic clustering
patterns. PCoA analysis was performed on the same high-quality monoclonal samples (n=615) by conducti was a specifical many of the same high-quality monoclonal samples (n=615) by conducting
measures using *sklearn.decomposition PCA* method of scikit-learn package version 1.2.0 on a microhaplotype
based pairwise distance ma patterns. The assures using *sklearn decomposition PCA* method of scikit-learn package version 1.2.0 on a microhaplotype-
based pairwise distance matrix calculated from the proportion of non-identical microphalotype allele measures using *skiearn.decomposition* PCA method of scikit fearn package version 1.2.0 on a micromaplotype
based pairwise distance matrix calculated from the proportion of non-identical microphalotype alleles across a
pos based pairwise included patterns were also assessed using IBD-based measures of differentiation
implemented with the hmmIBD package as described below and plotted using the R-based *igraph* package
(https://igraph.org).
A

positions. The interesting patterns were also assessed using the R-based igraph pa

(https://igraph.org).

A Bi-allele Likelihood (BALK) classifier was used to predict the country of origin of *P. vivox* isolates using

(inplemented with the minimibb package as described below and plotted using the R‐based *igraph* package (https://igraph.org).
A Bi-allele Likelihood (BALK) classifier was used to predict the country of origin of *P. vivax* A Bi-allele Likelihood
(not multi-allelic mic
barcode, and three rice BALK classifier ca
from 799 of the 922
with the sample set u ノ(l t f ヽ l A Bi allele Eikelihood (BALK) classifier was used to predict the country of origin of P. vivax isolates using SNP data
(not multi-allelic microhaplotypes) at biallelic SNPs in the High-diversity SNP microhaplotype panel, (not multi-allelic intertually dentified *P. vivax* geographic barcodes (GEO33, GEO50 and GEO55)^{21,28}. Details of
the BALK classifier can be found in the original paper²⁸. Country prediction performance was assessed us the BALK classifier can be found in the original paper²⁸. Country prediction performance was assessed using data
from 799 of the 922 high-quality samples in the available Pv4.0 genomic dataset. The 799 sample-set corresp the BALK classifier can be found in the original paper²². Country prediction performance was assessed using data
from 799 of the 922 high-quality samples in the available Pv4.0 genomic dataset. The 799 sample-set corresp with the sample set used in the original paper describing the BALK classifier²⁸. Briefly, the sample set was derived
by filtering samples to include a single representative of samples with near-identical genomes (define with the sample set used in the original paper describing the BALK classifier²⁸. Briefly, the sample set was derived
by filtering samples to include a single representative of samples with near-identical genomes (defined by filtering samples to include a single representative of samples with general genera with generation $\frac{1}{\sqrt{2}}$, subjecting to $\frac{1}{\sqrt{2}}$ and best representative data $\frac{1}{\sqrt{2}}$

missingness iteratively, and then removing samples that appeared to be imported based on genome-wide
clustering patterns. A total of 21 countries had ≥4 samples. The comparative predictive performance of t
panels was evalu mission of the SN panels was evaluated using a stratified 10-fold cross-validation with 500 repeats, reporting the Matthews
Correlation Coefficient (MCC).
Evaluation of IBD estimation with the microhaplotype panel
The 2

panels was evaluated using a stratified 10-fold cross-validation with 500 repeats, reporting the Matthews
Correlation Coefficient (MCC).
Evaluation of IBD estimation with the microhaplotype panel
The 2 selected microhapl parelation Coefficient (MCC).
 Evaluation of IBD estimation with the microhaplotype panel

The 2 selected microhaplotype panels (Random microhaplotype panel and High-diversity microhaplotype

as well as the 42-SNP Broad Evaluation of IBD estimation v
The 2 selected microhaplotype
as well as the 42-SNP Broad ba
relatedness (IBD) using a range
relatedness (r) ranging from 0 (
geographic regions. Details of t 1 - で 1 - ド ト **Evaluation of IBD estimation with the microhaplotype panel**
The 2 selected microhaplotype panels (Random microhaplotype panel and High-diversity microhaplotype panel), as well as the 42-SNP Broad barcode panel, were evaluated with *paneljudge* package for their ability to estimate
relatedness (IBD) using a range of simulations to compute the uncertainty (error rate) in estimations of
re as well as the 42–SNP Broad barcode panel, were evaluated with *paneljudge* package for their ability to estimate
relatedness (IBD) using a range of simulations to compute the uncertainty (error rate) in estimations of
re relatedness (r) range a range of strangers in all (identical) under varying allele frequency distributions in
geographic regions. Details of the equations, assumptions, and parameter options in the *paneljudge* pai
be fou relatedness (r) ranging from 0 (strangers) to 1 (identical) different varying allele riequency distributions in different
geographic regions. Details of the equations, assumptions, and parameter options in the *paneljudge* geographic regions. Details of the equations, assumptions, and parameter options in the paneljudge package can
be found on GitHub (https://github.com/aimeertaylor/paneljudge). Briefly, for each of a range of data-generati be found on a pair of haploid genotypes, generating 100
haploid genotype pairs. Estimates of $r(\hat{r})$, switch-rate parameter $k(\hat{k})$, the 95% confidence intervals (CIs) around
the estimates \hat{r} and \hat{k} , and root me *r* values (*r* = 0, 0.25, 0.5, 0.75 and 1.0), data were simulated on a pair of haploid genotypes, generating 100
haploid genotype pairs. Estimates of r (\hat{r}), switch-rate parameter k (\hat{k}), the 95% confidence haploid genotype pairs. Estimates of $Y(Y)$, switch-rate parameter $K(K)$, the 93% connuence intervals (CIs) around
the estimates \hat{r} and \hat{k} , and root mean square errors (RMSE) were then computed. The switch-rate pa the estimates r and n , and root mean square errors (KMSE) were then computed. The switch-rate platance modifies rate of switching between latent IBD and non-IBD states in the hidden Markov model by multiplying probabi modifies a crossover per base pair (default value 7.4e-7 as per ³⁷) and the inter-marker distance in base pairs
The accuracy of a given marker panel in estimating r was measured by the CI width and RMSE, ranging from ~0 probability of a crossover per base pair (default value 7.4e-7 as per ³⁷) and the inter-marker distance in base pairs.
The accuracy of a given marker panel in estimating r was measured by the CI width and RMSE, ranging The accuracy of a given marker panel in estimating *T* was incasured by the CI width and RMSE, ranging from σ (hear perfect informativeness) to 1 (uninformative). The CI width and RMSE of \hat{r} compared to the data-g The perfect informativeness) to 1 (uninformative). The er width and RMSE of T compared to the data generating
 T never reach 0 as a genome of finite length may have many realised relatednesses compatible with a given
 never all a general ends in the verifinite length may be some variance in realised relatedness around r. For
comparative value, *paneljudge* simulations were run on a panel of 100 single SNP markers (i.e., biallelic marl
a probability of IBD. This means that there will always be some variance in realised relatedness around 7.1 or
comparative value, *paneljudge* simulations were run on a panel of 100 single SNP markers (i.e., biallelic mar
an comparative value, panelyatge simulations were run on a panel of 100 single SNP markers (i.e., bialiene markers)
and for a set of 38 assayable biallelic SNPs from the 42-SNP Broad barcode that has been widely used by the

and for a set of 38 assayable biallelic SNP STOMT the 42-SNP biadd batcode that has been widely used by the P.

SNP in each microhaplotype.

In addition to simulation-based data, the efficacy of the selected microhaplotype vivax surveillance community^{22,38}. The 100-SNP biallelic panel was composed by selecting the highest diversity
SNP in each microhaplotype.
In addition to simulation-based data, the efficacy of the selected microhaplotyp SNP in each microhaplotype.
In addition to simulation-base
assessed relative to 'gold-star
with high-quality genomic dat
20.95). IBD estimates betwee
version 3 software does not e
reduce artificially the IBD esti | ・ ・ ・ ・ ハ = = = In a sessed relative to 'gold-standard' genome-wide data in pairs of primary (day 0) and recurrent *P. vivax* infect
with high-quality genomic data (≥50% genome covered by at least 5 reads) which were monoclonal infection assessed relative to 'gold'standard' genome wide data in pairs or primary (day or and recurrent P. vivax infections
with high-quality genomic data (\geq 50% genome covered by at least 5 reads) which were monoclonal infect which high quality genomic data (≥50% genome covered by at least 5 reads) which were monoclonal intections (F_{WS}

20.95). IBD estimates between infection pairs were generated using the *hmmlBD* version 3.0 software⁴⁰. ≥0.95). IBD estimates between infection pairs were generated using the *hmmIBD* version 3.0 software³⁶. As the version 3 software does not enable adjustments in the genotyping error rate for polyallelic markers (which m reduce artificially the IBD estimates between infections) the microhaplotype data were run as biallelic SNP
markers rather than polyallelic markers. Sample pairs were run in geographically defined batches using allele
freq reduce artificially defined batches using allements of markers rather than polyallelic markers. Sample pairs were run in geographically defined batches using allement infection and the regional estimates from the baseline markers rather than performance relative pairs from the baseline samples (high-quality, monoclonal,
independent infection) using default parameters. Genome-wide and microhaplotype-based recurrence
classifications were assi frequency estimates based on the regional estimates from the regional endphalotype-based recurrence
classifications were assigned using the following infection pair IBD thresholds; clone (pairwise IBD ≥0.95), cl
relative (classifications were assigned using the following infection pair IBD thresholds; clone (pairwise IBD ≥0.95 relative (0.25 \leq IBD <0.95), distant relative (0.05 \leq IBD <0.025), stranger (IBD <0.05). The concordance be relative (0.25≤ IBD <0.95), distant relative (0.05≤ IBD <0.25), stranger (IBD <0.05). The concordance between the microhaplotype and genome wide IBD estimates was evaluated by the correlation coefficient between the datas microhaplotype and genome wide IBD estimates was evaluated by the correlation coefficient between the datasets, and the proportion of recurrence classification mismatches.
datasets, and the proportion of recurrence classif datasets, and the proportion of recurrence classification mismatches.

And the correlation of the correlation coefficient between the correlation of the correlation coefficient between the correlation of the correlation of datasets, and the proportion of recurrence classification mismatches.

Ethics

studies with ethical approval from the local research ethics boards, and with written, informed consent provide
by patients or guardians for individuals of age 18 or younger²⁰.
Data availability
Sequencing data from the

Data availability

statues with ethical approximation in the local research ethical provides with the local provided in the local response both provided in a data note describing the MalariaGEN Pv4.0 data set²⁰.
With details provided in a by patients or guardians for individuals of age 18 or younger²⁰.
 Data availability

Sequencing data from these samples has been made publicly available in the European Nucleotide Archive (ENA),

with details provided

Code availability

Sequencing data from these samples has been made publicly available in the European Nucleotide Archives (ENA),
with details provided in a data note describing the MalariaGEN Pv4.0 data set²⁰.
Code availability
The custom with details provided in a data note describing the MalariaGEN Pv4.0 data set^{es}.
Code availability
The custom, in-house scripts used to select the microhaplotype panels are availa
https://github.com/svsiegel/vivax-mhaps.

Acknowledgements

The custom of the complete of the custom of the microhaplotter in the microhaplotter of the microhaplotter of the microhaplotter are used to the study, and the health worker https://wide.com/subside/viral.com/subside
Acknowledgements
We thank the patients who contributed th
assisted with the sample collections. Geno ノード We thank the patients who contributed their samples to the study, and the health workers and held teams who
assisted with the sample collections. Genome sequencing was undertaken by the Wellcome Sanger Institute and
we tha assisted with the sample collections. Genome sequencing was undertaken by the Wellcome Sanger Institute and
we thank the staff of the Wellcome Sanger Institute Sample Logistics, Sequencing, and Informatics facilities for
t

Funding

we their contribution.

Funding

The study was supported by the National Health and Medical Research Council of Australia (APP2001083

supporting, SA and SVS), the Wellcome Trust (200909 and ICRG GR071614MA Senior Fellowsh **Funding
The study was supp
supporting SA and
Science to RNP. 20** supporting SA and SVS), the Wellcome Trust (200909 and ICRG GR071614MA Senior Fellowships in Clinica
Science to RNP, 206194/217/Z supporting JCR and SVS) the National Institutes of Health (R01AI137154 to
the Bill & Melinda science to RNP, 206194/217/Z supporting JCR and SVS) the National Institutes of Health (R01AI137154 to Jule Bill & Melinda Gates Foundation (INV-043618 supporting SA and RNP). The whole genome sequencing component of the s the Bill & Melinda Gates Foundation (INV-043618 supporting SA and RNP).The whole genome sequencing
component of the study was supported by the Medical Research Council and UK Department for International
Development (award the Bill Accomponent of the study was supported by the Medical Research Council and UK Department for Internation
Development (award number M006212 to DK) and the Wellcome Trust (award numbers 206194 and 2049
DK). The IMPR component (award number M006212 to DK) and the Wellcome Trust (award numbers 206194 and 204911 to
DK). The IMPROV clinical trial was supported by the Bill & Melinda Gates Foundation (OPP1054404 awarded to
RNP).
MRNP). DR). The IMPROV clinical trial was supported by the Bill & Melinda Gates Foundation (OPP1054404 awarded to RNP).
DK). The IMPROV clinical trial was supported by the Bill & Melinda Gates Foundation (OPP1054404 awarded to
RN RNP). RNP).

Tables

Table 1. Geographic distribution of the sample set.

Malaysia (MSEA), Indonesia and Papua New Guinea (OCE), Brazil, Colombia, El Salvador, Mexico, Nicaragua and
Peru (SAM), Afghanistan, India and Iran (WAS), and Thailand (WSEA). The Thai samples in ESEA and in WSEA
derive fr Malaysia (SAM), Afghanistan, India and Iran (WAS), and Thailand (WSEA). The Thai samples in ESEA and in WSEA
derive from provinces east and west respectively of a previously described malaria-free corridor that runs throu
 derive from provinces east and west respectively of a previously described malaria-free corridor that runs th
the centre of Thailand⁴².
The Thailand in Washington Washington Washington Washington Thailand (Washington). the centre of Thailand 42 . the centre of Thailand⁴².
And Thailand
And Thailand

Table 2. Genome-wide versus microhaplotype-based identity by descent (IBD) estimates in P. vivax infection pairs. List of sample pairs evaluated for relatedness as a fraction of the genome IBD using genome-wide and microhaplotype-based data. IBD fractions were determined using hmmIBD software, with microhaplotype variants analysed as biallelic SNPs. Clinical survey treatments; TQ (tafenoquine), PQ (primaquine), AS (artesunate), CQ (chloroquine), AM (artesunate-mefloquine). *Recurrence classification; clone (IBD≥0.95), close relative (0.25≤IBD<0.95), distant relative (0.05≤IBD<0.25), stranger (IBD<0.05). **Returning travellers presenting at the Royal Darwin Hospital, Darwin, Australia.

 Table 3. Regional patterns of population diversity using the High-diversity microhaplotype panel. Measures were conducted on n= 615 high-quality biologically independent monoclonal samples.

Table 4. Regional patterns of within-host infection diversity. Measures were conducted on n=922 high-quality biologically independent samples. *Pearson's Chisquared test with Yates' continuity correction. **1-sided Mann-Whitney U testing the hypothesis that the Fws in the COI=1 infection group is not larger than in the COI>1 infection group.

Table 5. Summary of median MCC scores from comparative evaluations of country prediction performance between the SNP panels. Comparisons were undertaken between the 494 SNPs in the High-diversity microhaplotype panel (MHAP-3_10), the 38-SNP Broad barcode (BR38), and the 33-, 50- and 55-SNP GEO panels (GEO33, GEO50 and GEO55 respectively). The median Mathews correlation coefficient (MCC) summary statistics

are based on 500 repeats of the stratified 10-fold cross-validation using the Bi-Allele Likelihood (BALK) classifier in a set of n [2=2799 biologically independent samples from 21 countries (each with n \geq 4)²⁸.

Figure 1. Microhaplotype discovery pipeline. Panel a) provides an overview of the marker selection process. Criteria for selecting samples, variants, and windows for potential microhaplotype candidate windows result in a total of 5,460 windows (200 bp). The MalariaGEN Pv4 dataset was filtered to use only high-quality monoclona samples (Fws ≥0.95) that had at least 50% of the core genome positions callable. SNP variants from this sample subset were then identified as biallelic, have low genotype missingness (<0.1), had high global minor allele frequencies (MAF ≥0.1), and FILTER = PASS in the MalariaGEN dataset, resulting in 13,090 total SNPs. The co genome was then scanned in coding regions for all 200 bp windows in which > 1 of the identified variants were found and filtered for high diversity (glo obal heterozygosity ≥0.5). Panel b) provides a schematic representation of microhaplotypes with 3 SNPs. Microhaplotypes leverage SNP information content in smallwindowed regions of the genome to provide a high-resolution reconstruction of the parasite genome. Three high-diversity SNPs in a single microhaplotype can have as many as 8 distinct combinations of alleles which, when combined with 100 microhaplotypes across the genome, results in high discriminatory power to characterize relatedness. Panel c) provides a map of the P. vivax heterozygome. Chromosomal distribution of all windows identified in the global set of high-quality, independent monoclonal infections with at least 1 SNP. Each point is an identified window, with the size increasing as the number of SNPs within the window increases. Potential microhaplotype regions are well distributed across the 14 chromosomes. The microhaplotypes with the highest SNP densities tend to be located at the ends of the chromosomes. Note, microhaplotypes were selected only from the accessible regions of the genome i.e., excluding highly diverse telomeric and sub-telomeric regions where sequence reads could not be mapped accurately. Panel d) illustrates the chromosome distribution of three panels evaluated for their capacity to reconstruct parasite relatedness. Two new microhaplotype panels were created from the microhaplotype discovery pipeline, named "Random mhaps" plotted in orange, and "Highdiversity mhaps" plotted in purple. These two panels were selected to have 100 microhaplotype markers using windows that were well-spaced and had between 3-10 SNPS, with even distribution across all 14 chromosomes and a minimum diversity with heterozygosity ≥0.5. The markers for the Random mhaps panel were selected randomly, while the High-diversity mhaps panel were optimised to have the highest heterozygosity possible in each region. These two high-resolution panels were compared to the currently used biallelic 42-SNP panel, named "Broad" in green. Only 38 markers of this panel are considered informative and included in this representation.

Figure 2. Confidence intervals around relatedness estimates based on data simulated using various datagenerating relatedness parameters, r. Data are presented on 3 marker panels: High-diversity microhaplotype panel, Random-SNP microhaplotype panel, and 38 Broad barcode biallelic SNPs. Separate plots are provided for each r and geographic region; AF (Africa), ESEA (East Southeast Asia), MSEA (Maritime Southeast Asia), OCE (Oceania), SAM (South America), WAS (West Asia) and WSEA (West Southeast Asia).

Figure 3. Comparative diversity between the High-diversity microhaplotype panel and the 38-SNP Broad Barcode. Panel a) presents heterozygosity measures and panel b) presents effective cardinality scores in n=615 high-quality biologically independent monoclonal samples by panel and region. Panel labels; 38-SNP Broad barcode (BR38) and High-diversity microhaplotype panel (MHAP-3_10). Regional labels; Africa (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS) and West Southeast Asia (WSEA).

Figure 5. Spatial trends in P. vivax connectivity using microhaplotypes. Panels a) presents a PCoA plot presenting PC1 (46.4%) against PC2 (25.3%) in n= 615 high-quality biologically independent monoclonal isolates from Pv4.0 at the High-diversity SNP microhaplotype set. The combinations of PC1 and PC2 provides marked separation of all 7 regional groups. Panels b) and c) present whole genome sequencing (WGS) and microhaplotype-based IBD infection networks in Malaysia. The network plots were generated at a set of 224,612 SNPs (WGS) and the High-diversity SNP microhaplotype panel in single clone Malaysian infections (n=57) at a connectivity threshold of minimum IBD 0.5 (siblings or greater relatedness). Infections are colour-coded according to sub-structure definitions based on previously described ADMIXTURE analysis with genomic data²⁷. Infections defined as "New" (purple) were not available in the previous analysis. The clustering patterns of the WGS and microhaplotype-based data are highly consistent; both data sets capture high connectivity amongst the K2 outbreak strains, a distinct K3 sub-population, and divergent K4 infections²⁷. The new infections appear to derive from across the different sub-populations.

Figure 6. Comparison of country prediction performance between SNP panels. Comparisons were undertaken between the 494 SNPs in the High-diversity microhaplotype panel (MHAP-3_10), the 38-SNP Broad barcode (BR38), and the 33-, 50- and 55-SNP GEO panels (GEO33, GEO50 and GEO55 respective ely). The boxplo present the Mathews correlation coefficient (MCC) scores from 500 repeats with stratified 10-fold cross validation for each SNP set using the Bi-Allele Likelihood classifier²⁸. Country labels are provided on the y-axis. Each bar presents the median, interquartile range and minimum and maximum MCC for the given country and model. The analyses were based on n_{[2}=799 biologically independent samples from 21 countries (each with n ≥4 samples).

Supplementary Material

 Supplementary Table 1. Microhaplotype panel marker selection information.

Supplementary Table 2. Properties of the three most diverse markers in each geographic region for the High-diversity microhaplotype panel. *The PvP01_05_v1:1369384:7,52,99,114,121,126,136,164 microhaplotype was one of the top three most diverse markers in all seven geographic regions.

Supplementary Figure 1. *P. viva***x incidence map illustrating regional country groupings.** The baseline *P. vivax* incidence map was derived from the Malaria Atlas Proj (MAP) and presents the number of newly diagnosed *P. vivax* cases per 1,000 population in 2020⁴¹. The labelled, dashed red lines indicate the boundaries of the geographic regions included in the identity by descent (IBD) analyses: SAM (South America), AF (Africa), WAS (West Asia), WSEA (West Southeast Asia) , ESEA (East Southeast Asia), MSEA (Maritime Southeast Asia) and OCE (Oceania). Pinpoints indicate the countries included in each regional grouping.

Supplementary Figure 2. Comparative accuracy in relatedness prediction at Random and High-diversity microhaplotype panels, and the 38-SNP Broad barcode. Root mean square error (RMSE) of relatedness estimates
based on data simulated using various data-generating relatedness and switch rate parameters, r and k, based on data simulated using various data-generating relatedness and switch rate parameters, r and k, respectively. Data are presented on 3 marker panels: High-diversity SNP microhaplotype panel, Random-SNP microhaplotype panel and 38 Broad barcode biallelic SNPs. Panel comparisons are presented by geographic region; AF (Africa), ESEA (East Southeast Asia), MSEA (Maritime Southeast Asia), OCE (Oceania), SAM (South America), WAS (West Asia) and WSEA (West Southeast Asia).

Supplementary Figure 3. Correlations between microhaplotype and genomic estimates of IBD in the regional datasets. Panels a) to g) represent Afric ca (AF), East Southeast Asia (ESEA), Maritime Southeast Asia (MSEA), Oceania (OCE), South America (SAM), West Asia (WAS), and West Southeast Asia (WSEA). The microhaplotype and whole genome sequence (WGS) IBD estimates reflect pairwise estimates at the High-diversity SNP microhaplotype panel and a set of 898,448 geno ome-wide SNPs calculations were performed using *hmmIBD* on the 615 monoclonal sample set. Correlations were assessed with Spearman's rho statistic (using a paired test) and presented with the associated p-value. At an alpha of 0.05, significantly positive correlations were observed in all regions.

Supplementary Figure 4. Regional microhaplotype-based infection networks. Panels a) to e) represent South America (SAM), Africa (AF), West Asia (WAS), West Southeast Asia (WSEA), East Southeast Asia (ESEA) and Oceania (OCE). The networks were generated from the High-diversity SNP microhaplotype panel in the 615 monoclonal sample set. The isolates from Maritime Southeast Asia (MSEA) were mostly from Malaysia (57/59) and are represented in Figure 5. Each ci rcle reflects an infection, colour-coded by country, and line lengths reflect relatedness (shorter lines reflect greater relatedness) at a connectivity threshold of minimu m identity by descent (IBD) 0.25 (half-siblings or greater relatedness). Each circle reflects an infection, with colour-coding by country.

References

-
-
- $\frac{1}{2}$ Auburn, S., Cheng, Q., Marfurt, J. & Price, R. N. The changing epidemiology of Plasmoc
vivax: Insights from conventional and novel surveillance tools. *PLoS medicine* 18, e10C
doi:10.1371/journal.pmed.1003560 (2021).
Commo vivax: Insights from conventional and novel surveillance tools. PLoS medicine 18, e1003560

doi:10.1371/journal.pmed.1003560 (2021).

Commons, R. J., Simpson, J. A., Watson, J., White, N. J. & Price, R. N. Estimating the
 vivax: Insights from conventional and novel surveillance tools. PLoS medicine 18, e1003500,
doi:10.1371/journal.pmed.1003560 (2021).
Commons, R. J., Simpson, J. A., Watson, J., White, N. J. & Price, R. N. Estimating the
Pr Commons, R. J., Simpson, J. A., Watson, J., V
Proportion of Plasmodium vivax Recurrence
Meta-Analysis. The American journal of trop
doi:10.4269/ajtmh.20-0186 (2020).
White, N. J. Determinants of relapse periodi
journal **10** Proportion of Plasmodium vivax Recurrences Caused by Relapse: A Systematic Revistmental Meta-Analysis. The American journal of tropical medicine and hygiene 103, 1094-10
doi:10.4269/ajtmh.20-0186 (2020).
White, N. J. Deter
-
- Meta-Analysis. The American journal of tropical medicine and hygiene 103, 1094-1099,
doi:10.4269/ajtmh.20-0186 (2020).
White, N. J. Determinants of relapse periodicity in Plasmodium vivax malaria. *Malaria*
journal 10, 297 Meta-Analysis. *The American Journal of tropical medicine and hygiene* 103, 1034-1035, doi:10.4269/ajtmh.20-0186 (2020).
White, N. J. Determinants of relapse periodicity in Plasmodium vivax malaria. *Malaria*
journal 10, 2 White, N. J. Determinants of relapse
journal 10, 297, doi:10.1186/1475-2
Price, R. N. *et al.* Global extent of ch
review and meta-analysis. The Lance
3099(14)70855-2 (2014).
von Seidlein, L. *et al.* Review of key l
dehyd
- Figurial 10, 297, doi:10.1186/1475-2875-10-297 (2011).

Price, R. N. *et al.* Global extent of chloroquine-resistant Plasmodium vivax: a systemative review and meta-analysis. *The Lancet. Infectious diseases* 14, 982-991, journal 10, 297, doi:10.1186/1475-2875-10-297 (2011).
Price, R. N. *et al.* Global extent of chloroquine-resistant Plasmodium vivax: a systematic
review and meta-analysis. The Lancet. Infectious diseases 14, 982-991, doi:1 Frice, R. N. et al. Global extent of chloroquine-resistant Plasmodium vivax: a systematic
review and meta-analysis. The Lancet. Infectious diseases 14, 982-991, doi:10.1016/S14;
3099(14)70855-2 (2014).
von Seidlein, L. *et* review and meta-analysis. The Lancet. Infectious diseases 14, 582-551, doi:10.1010/51475-3099(14)70855-2 (2014).
3099(14)70855-2 (2014).
von Seidlein, L. *et al.* Review of key knowledge gaps in glucose-6-phosphate
dehydro von Seidlein, L. *et al.* Revidehydrogenase deficiency
dehydrogenase deficiency
aminoquinoline treatmen
doi:10.1186/1475-2875-1
Thriemer, K. *et al.* Challen
vivax: a round table discu
141, doi:10.1186/s12936-For Seidlein, E. et al. Review of key knowledge gaps in glucose-0-phosphate
dehydrogenase deficiency detection with regard to the safe clinical deploym
aminoquinoline treatment regimens: a workshop report. *Malaria journal*
- aminoquinoline treatment regimens: a workshop report. *Malaria journal* 12, 112,
doi:10.1186/1475-2875-12-112 (2013).
Thriemer, K. *et al*. Challenges for achieving safe and effective radical cure of Plasmod
vivax: a round aminoquinoline treatment regimens: a workshop report. Malaria journal 12, 112,
doi:10.1186/1475-2875-12-112 (2013).
Thriemer, K. *et al.* Challenges for achieving safe and effective radical cure of Plasm
vivax: a round tab Thriemer, K. *et al.* Challenges for achiev
vivax: a round table discussion of the AF
141, doi:10.1186/s12936-017-1784-1 (2
Cheah, P. Y., Steinkamp, N., von Seidleir
randomised controlled trials: a case stua
medical ethics
- Findemer, K. et al. Challenges for achieving safe and effective radical cure of Fiasmodium
vivax: a round table discussion of the APMEN Vivax Working Group. *Malaria journal* 16,
141, doi:10.1186/s12936-017-1784-1 (2017).
 Cheah, P. Y., Steinkamp, N., von Seidlein, L. &
Cheah, P. Y., Steinkamp, N., von Seidlein, L. &
randomised controlled trials: a case study of a
medical ethics 19, 19, doi:10.1186/s12910-01
Snounou, G. & Beck, H. P. The use
- vivax: a round table discussion of the APMEN Vivax Working Group. Malarid Journal 16,
141, doi:10.1186/s12936-017-1784-1 (2017).
Cheah, P. Y., Steinkamp, N., von Seidlein, L. & Price, R. N. The ethics of using placebo in
r 8 randomised controlled trials: a case study of a Plasmodium vivax antirelapse trial. *BMC*

8 medical ethics **19**, 19, doi:10.1186/s12910-018-0259-4 (2018).

8 Snounou, G. & Beck, H. P. The use of PCR genotyping in the as randomised controlled trials: a case study of a Frasmodium vivax antiferapse trial. *BMC*
medical ethics 19, 19, doi:10.1186/s12910-018-0259-4 (2018).
Snounou, G. & Beck, H. P. The use of PCR genotyping in the assessment o medical ethics 13, 19, doi:10.11887312310-018-0233-4 (2018).
Snounou, G. & Beck, H. P. The use of PCR genotyping in the ass
or reinfection after antimalarial drug treatment. *Parasitol Toda*
doi:10.1016/s0169-4758(98)01340
- or reinfection after antimalarial drug treatment. *Parasitol Today* 14, 462-467,

doi:10.1016/s0169-4758(98)01340-4 (1998).

Chen, N., Auliff, A., Rieckmann, K., Gatton, M. & Cheng, Q. Relapses of Plasmodium vivax

infecti
- or reinfection after antimalarial drug treatment. Partishon Today 14, 462-467,
doi:10.1016/s0169-4758(98)01340-4 (1998).
Chen, N., Auliff, A., Rieckmann, K., Gatton, M. & Cheng, Q. Relapses of Plasmo
infection result from Chen, N., Auliff, A., Rieckmann, K., Gatton, M
infection result from clonal hypnozoites activ
of infectious diseases 195, 934-941, doi:10.10
Imwong, M. et al. Relapses of Plasmodium viv
heterologous hypnozoites. The Journa 11 Intertion result from clonal hypnozoites activated at predetermined intervals. The Journa
11 of infectious diseases 195, 934-941, doi:10.1086/512242 (2007).
11 Inwong, M. et al. Relapses of Plasmodium vivax infection us heterologous hypnozoites. The Journal of infectious diseases 195, 927-933,
- infection result from clonal hypnozoites activated at predetermined intervals. The Journal
of infectious diseases **195**, 934-941, doi:10.1086/512242 (2007).
Imwong, M. *et al.* Relapses of Plasmodium vivax infection usuall 11 Imwong, W. et al. Relapses of Plasmodial Vivax infection usually result from activation of
heterologous hypnozoites. The Journal of infectious diseases 195, 927-933,
doi:10.1086/512241 (2007).
Cowell, A. N., Valdivia, H heterologous hypnozoites. The Journal of infectious diseases 199, 927-933,
doi:10.1086/512241 (2007).
Cowell, A. N., Valdivia, H. O., Bishop, D. K. & Winzeler, E. A. Exploration of P
vivax transmission dynamics and recurre Cowell, A. N., Valdivia, H. O.,
vivax transmission dynamics
genome sequencing. *Genom*
Bright, A. T. *et al*. A high resc
infections shows that relapse
diseases 8, e2882, doi:10.13
Popovici, J. *et al.* Recrudesce
- vivax transmission dynamics and recurrent infections in the Peruvian Amazon using wh
genome sequencing. *Genome Med* 10, 52, doi:10.1186/s13073-018-0563-0 (2018).
Bright, A. T. *et al*. A high resolution case study of a pa
- vivation dependence and *senome Med* **10**, 52, doi:10.1186/s13073-018-0563-0 (2018).
Bright, A. T. *et al.* A high resolution case study of a patient with recurrent Plasmodium viva:
infections shows that relapses were caus genome sequencing. Semante Med 10, 32, doi:10.1188/s13073-018-0583-0 (2018).
Bright, A. T. *et al.* A high resolution case study of a patient with recurrent Plasmodiu
infections shows that relapses were caused by meiotic s 13 Bright, A. T. et al. A high resolution case study of a patient with recurrent Plasmodium vivax
infections shows that relapses were caused by meiotic siblings. *PLoS neglected tropical
diseases* 8, e2882, doi:10.1371/jou diseases 8, e2882, doi:10.1371/journal.pntd.0002882 (2014).
Popovici, J. *et al.* Recrudescence, Reinfection, or Relapse? A More Rigorous Framework
Assess Chloroquine Efficacy for Plasmodium vivax Malaria. The Journal of i diseases **d**, e2882, doi:10.1371/journal.pntd.0002882 (2014).
Popovici, J. *et al.* Recrudescence, Reinfection, or Relapse? A M
Assess Chloroquine Efficacy for Plasmodium vivax Malaria. Th
diseases **219**, 315-322, doi:10.1 14 Popovici, J. et al. Recrudescence, Reinfection, or Relapse? A More Rigorous Framework to
Assess Chloroquine Efficacy for Plasmodium vivax Malaria. The Journal of infectious
diseases 219, 315-322, doi:10.1093/infdis/jiy4 Assess Chloroquine Efficacy for Plasmodium vivax Malaria. The Journal of infectious
diseases 219, 315-322, doi:10.1093/infdis/jiy484 (2019).
36 diseases 219, 315-322, doi:10.1093/infdis/jiy484 (2019).

-
- 15 Taylor, A. R. et al. Quantifying connectivity between local Tashiodian ratelyatin malaria
parasite populations using identity by descent. *PLoS genetics* 13, e1007065,
doi:10.1371/journal.pgen.1007065 (2017).
Noviyanti, parasite populations using identity by descent: 7 Los genetics 13, e1007003,
doi:10.1371/journal.pgen.1007065 (2017).
Noviyanti, R. *et al.* Implementing parasite genotyping into national surveillar
frameworks: feedback fr Moviyanti, R. *et al.* Implementing parasite g
frameworks: feedback from control program
Malaria journal 19, 271, doi:10.1186/s1293
Jacob, C. G. *et al.* Genetic surveillance in the
support malaria control and eliminatio 16 Noviyanti, R. et al. Implementing parasite genotyping into national surventince
frameworks: feedback from control programmes and researchers in the Asia-Pa
Malaria journal **19**, 271, doi:10.1186/s12936-020-03330-5 (20
-
-
- *Malaria journal* 19, 271, doi:10.1186/s12936-020-03330-5 (2020).
Jacob, C. G. *et al.* Genetic surveillance in the Greater Mekong subregion and South Asia to
support malaria control and elimination. *eLife* 10, doi:10.755 Malaria journal 19, 271, doi:10.1188/312330-020-03330-3 (2020).
Jacob, C. G. *et al.* Genetic surveillance in the Greater Mekong subre
support malaria control and elimination. *eLife* 10, doi:10.7554/eLif
Taylor, A. R., Ja Sacob, C. G. et al. Genetic surveillance in the Greater Mekong subregion and South Asia to
support malaria control and elimination. *eLife* 10, doi:10.7554/eLife.62997 (2021).
Taylor, A. R., Jacob, P. E., Neafsey, D. E. & support malaria control and elimination. *eLife* **10**, doi:10.7554/eLife.62997 (2021).
Taylor, A. R., Jacob, P. E., Neafsey, D. E. & Buckee, C. O. Estimating Relatedness Between
Malaria Parasites. *Genetics* **212**, 1337-13 Malaria Parasites. *Genetics* 212, 1337-1351, doi:10.1534/genetics.119.302120 (2019).

18 Tessema, S. K. *et al.* Sensitive, Highly Multiplexed Sequencing of Microhaplotypes From the Plasmodium falciparum Heterozygome. *Th* Malaria Parasites. Genetics 212, 1337-1331, doi:10.1334/genetics.119.302120 (2013).
Tessema, S. K. *et al.* Sensitive, Highly Multiplexed Sequencing of Microhaplotypes Fron
Plasmodium falciparum Heterozygome. *The Journal*
- 19 Tessema, S. K. et al. Sensitive, Highly Multiplexed Sequencing of Microhaplotypes From the

Plasmodium falciparum Heterozygome. The Journal of infectious diseases 225, 1227-1237,

doi:10.1093/infdis/jiaa527 (2022).

Mal
- rlasmodium falciparum fleterozygome. The Journal by injectious diseases 225, 1227-1237,
doi:10.1093/infdis/jiaa527 (2022).
MalariaGen *et al.* An open dataset of Plasmodium vivax genome variation in 1,895
worldwide samples MalariaGen *et al.* An open dataset of Plasmodium vivax genome variation in 1,895
worldwide samples. Wellcome open research **7**, 136,
doi:10.12688/wellcomeopenres.17795.1 (2022).
Baniecki, M. L. *et al.* Development of a s MalariaGen et al. An open dataset of Plasmodium vivax genome variation in 1,895
worldwide samples. Wellcome open research 7, 136,
doi:10.12688/wellcomeopenres.17795.1 (2022).
Baniecki, M. L. *et al.* Development of a singl worldwide samples. Wencome oper research 7, 130,
doi:10.12688/wellcomeopenres.17795.1 (2022).
Baniecki, M. L. *et al.* Development of a single nucleot
genotype Plasmodium vivax infections. *PLoS neglecte*
doi:10.1371/journ Baniecki, M. L. *et al.* Development of a single nuc
genotype Plasmodium vivax infections. *PLoS negl*
doi:10.1371/journal.pntd.0003539 (2015).
LaVerriere, E. *et al.* Design and implementation o
to serve genomic epidemiol
- Example Plasmodium vivax infections. PLoS neglected tropical diseases 9, e000353
doi:10.1371/journal.pntd.0003539 (2015).
LaVerriere, E. et al. Design and implementation of multiplexed amplicon sequencin
to serve genomic e genotype Plasmodium vivax infections. P*Los neglected tropical diseases 3,* e0003333,
doi:10.1371/journal.pntd.0003539 (2015).
LaVerriere, E. *et al.* Design and implementation of multiplexed amplicon sequencing p
to serve LaVerriere, E. *et al.* Design and implementato serve genomic epidemiology of infectiou
22, 2285-2303, doi:10.1111/1755-0998.136
Lacerda, M. V. G. *et al.* Single-Dose Tafenoo
Malaria. *The New England journal of medic*
(2
- 22 Laverriere, E. et al. Design and implementation of multiplexed amplicon sequencing panels
to serve genomic epidemiology of infectious disease: A malaria case study. *Mol Ecol Resour*
22, 2285-2303, doi:10.1111/1755-0998 to serve genomic epidemiology of infectious disease: A malaria case study. Morecorresour
22, 2285-2303, doi:10.1111/1755-0998.13622 (2022).
Lacerda, M. V. G. *et al.* Single-Dose Tafenoquine to Prevent Relapse of Plasmodiu
- 22, 2285-2303, doi:10.1111/1755-0998.13622 (2022). Example 123 Lacerda, M. V. S. et al. Single-Dose Tafenoquine to Prevent Relapse of Flasmodium Vivax

Malaria. The New England journal of medicine 380, 215-228, doi:10.1056/NEJMoa171077

(2019).

Taylor, W. R. J. et al. Sho
- Malaria. The New England Journal of medicine 380, 213-228, doi:10.1056/NEJMoa1710775
(2019).
Taylor, W. R. J. et al. Short-course primaquine for the radical cure of Plasmodium vivax
malaria: a multicentre, randomised, plac (2019).

Taylor, W. R. J. *et al.* Short-course primaquine for the radical cure of Plasmodium vivax

malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *Lancet* **394**,

929-938, doi:10.1016/S014 24 Taylor, W. R. J. et al. Short-course primaquine for the radical cure of Hashiodian Viva

malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. *Lancet* 394

929-938, doi:10.1016/S0140-6736(19)312 malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet 334,
929-938, doi:10.1016/S0140-6736(19)31285-1 (2019).
Chu, C. S. *et al.* Comparison of the Cumulative Efficacy and Safety of Chloroqui Chu, C. S. *et al.* Comparison of the Cumulative Efficacy and Safety of Chloroquine,
Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. *Clinical inf*
diseases : an official publication of the Infectious D
- 25 Chu, C. S. et al. Comparison of the Cumulative Efficacy and Safety of Chloroquine,

Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. Clinical inf

diseases : an official publication of the Infectious Artesunate, and Chloroquine-Primaquine in Plasmodium vivax Malaria. C*linical infectious*
diseases : an official publication of the Infectious Diseases Society of America **67**, 1543-
1549, doi:10.1093/cid/ciy319 (2018).
Gr diseases : an official publication of the Infectious Diseases Society of America 67, 1545-1549, doi:10.1093/cid/ciy319 (2018).
Grigg, M. J. *et al.* Efficacy of Artesunate-mefloquine for Chloroquine-resistant Plasmod
vivax Grigg, M. J. et al. Efficacy of Artesunat

vivax Malaria in Malaysia: An Open-la

diseases : an official publication of the

doi:10.1093/cid/ciw121 (2016).

Auburn, S. et al. Genomic analysis of a

population reveals selec 26 Grigg, M. J. et al. Emcacy of Artesunate-memoquine for Chloroquine-resistant Plasmodium

26 Vivax Malaria in Malaysia: An Open-label, Randomized, Controlled Trial. Clinical infectious

26 discusses: an official publicat
- vivax Malaria in Malaysia: All Open-label, Randomized, Controlled Trial. Clinical injectious
diseases : an official publication of the Infectious Diseases Society of America,
doi:10.1093/cid/ciw121 (2016).
Auburn, S. et al doi:10.1093/cid/ciw121 (2016).
doi:10.1093/cid/ciw121 (2016).
Auburn, S. *et al.* Genomic analysis of a pre-elimination Malaysian Plasmodium
population reveals selective pressures and changing transmission dynamics. A
com Auburn, S. *et al.* Genomic analys
population reveals selective pre:
communications 9, 2585, doi:10
Trimarsanto, H. *et al.* A molecula
imported Plasmodium vivax mal
04352-2 (2022).
Taylor, A. R. *et al.* Resolving the
- 27 Auburn, 3. et al. Genomic analysis of a pre-elimination Malaysian Plasmodium vivax

population reveals selective pressures and changing transmission dynamics. Nature

communications 9, 2585, doi:10.1038/s41467-018-04965 population reveals selective pressures and changing transmission dynamics. Nature
communications 9, 2585, doi:10.1038/s41467-018-04965-4 (2018).
Trimarsanto, H. *et al.* A molecular barcode and web-based data analysis tool communications 9, 2585, doi:10:1050/341467-018-04505-4 (2018).
Trimarsanto, H. *et al.* A molecular barcode and web-based data ana
imported Plasmodium vivax malaria. *Commun Biol* 5, 1411, doi:10.1
04352-2 (2022).
Taylor,
- 28 Trimarsanto, H. et al. A molecular barcode and web-based data analysis tool to identify

imported Plasmodium vivax malaria. Commun Biol 5, 1411, doi:10.1038/s42003-022-

04352-2 (2022).

Taylor, A. R. *et al.* Resolving mported Plasmodium vivax malaria. Commun Biol 5, 1411, doi:10.1038/s42003-022-04352-2 (2022).
Taylor, A. R. *et al.* Resolving the cause of recurrent Plasmodium vivax malaria
probabilistically. *Nature communications* **10** Taylor, A. R. *et a*
probabilistically.
(2019).
Popovici, J. *et al.*
Plasmodium viva 29 Taylor, A. R. et al. Resolving the cause of recurrent Plasmodium Vivax malaria
probabilistically. *Nature communications* 10, 5595, doi:10.1038/s41467-019-1
(2019).
Popovici, J. *et al.* Genomic Analyses Reveal the Comm
- probabilistically. Nature communications 10, 5555, doi:10.1030/341407-015-13412-x
(2019).
Popovici, J. *et al.* Genomic Analyses Reveal the Common Occurrence and Complexity (Plasmodium vivax Relapses in Cambodia. *mBio* 9, (2019).
Popovic
Plasmoo Popovici, J. et al. Genomic Analyses Reveal the Common Occurrence and Complexity of
Plasmodium vivax Relapses in Cambodia. mBio 9, doi:10.1128/mBio.01888-17 (2018).
37 Plasmodium vivax Relapses in Cambodia. *mbio* 9, doi:10.1128/mBio.01888-17 (2018).

- 31
- method to calculate genetic distance between polyclonal infections. *Genetics* 222,

32 doi:10.1093/genetics/iyac126 (2022).

32 Parobek, C. M. *et al.* Selective sweep suggests transcriptional regulation may underlie

21 method to calculate genetic distance between polyclonal infections. Genetics 222,
doi:10.1093/genetics/iyac126 (2022).
Parobek, C. M. *et al.* Selective sweep suggests transcriptional regulation may under
Plasmodium vivax Parobek, C. M. *et al.* Selective sweep s
Plasmodium vivax resilience to malaria
Mational Academy of Sciences of the U
doi:10.1073/pnas.1608828113 (2016)
Lo, E. *et al.* Frequent expansion of Plas
its epidemiological signi Franchek, C. M. et al. Selective sweep suggests transcriptional regulation may underlie

Plasmodium vivax resilience to malaria control measures in Cambodia. Proceedings of

National Academy of Sciences of the United State
- Plasmodium vivax resilience to malaria control measures in Cambodia. Proceedings of the
National Academy of Sciences of the United States of America 113, E8096-E8105,
doi:10.1073/pnas.1608828113 (2016).
Lo, E. et al. Frequ
- National Academy of Sciences of the Onted States of America 113, E8098-E8103,
doi:10.1073/pnas.1608828113 (2016).
Lo, E. *et al.* Frequent expansion of Plasmodium vivax Duffy Binding Protein in Ethi
its epidemiological sig Lo, E. *et al.* Frequent expansion of Plasits epidemiological significance. *PLoS nedoi:10.1371/journal.pntd.0007222 (2016).*
doi:10.1371/journal.pntd.0007222 (2016).
Hupalo, D. N. *et al.* Population genomic
drug resistan 23 Lo, E. et al. Frequent expansion of Plasmodium vivax Dury Binding Protein in Ethiopia and
its epidemiological significance. PLoS neglected tropical diseases 13, e0007222,
doi:10.1371/journal.pntd.0007222 (2019).
Hupalo, its epidemiological significance. PLoS neglected tropical diseases 13, e0007222,
doi:10.1371/journal.pntd.0007222 (2019).
Hupalo, D. N. *et al.* Population genomics studies identify signatures of global dis
drug resistance Hupalo, D. N. *et al.* Population genomics st
drug resistance in Plasmodium vivax. Natur
(2016).
Auburn, S. *et al.* Characterization of within-
next-generation sequence data. *PloS one* 7
(2012).
Chang, H. H. *et al.* THE
- 34 Hupalo, D. N. et al. 1 opdiation genomics staties identity signatures or global dispersal and
drug resistance in Plasmodium vivax. Nature genetics 48, 953-958, doi:10.1038/ng.3588
(2016).
Auburn, S. et al. Characterizat
- drug resistance in Frasmodium vivax. Nature genetics 48, 933-938, doi:10.1038/ng.3588
(2016).
Auburn, S. *et al.* Characterization of within-host Plasmodium falciparum diversity using
next-generation sequence data. *PloS o* (2016).

Auburn, S. *et al.* Characterization of within-host Plasmodium falciparum diversity using

next-generation sequence data. *PloS one* **7**, e32891, doi:10.1371/journal.pone.0032891

(2012).

Chang, H. H. *et al.* T Auburn, S. et al. Characterization of Within-host Plasmodium faltiparum diversity dsing
next-generation sequence data. *PloS one* 7, e32891, doi:10.1371/journal.pone.0032891
(2012).
Chang, H. H. *et al.* THE REAL McCOIL: A next-generation sequence data. *PloS one* 7, e32891, doi:10.1371/journal.pone.0032891
(2012).
Chang, H. H. *et al.* THE REAL McCOIL: A method for the concurrent estimation of the
complexity of infection and SNP allele freq Chang,
Comple,
comple,
13, e10
Miles, A
Plasmoo
(2016).
Dewasu
- Softening, H. H. et al. THE REAL McCOIL: A method for the concurrent estimation of the
complexity of infection and SNP allele frequency for malaria parasites. PLoS Comput.
13, e1005348, doi:10.1371/journal.pcbi.1005348 (20 complexity of infection and SNP allele frequency for malaria parasites. PLoS Comput Biol
13, e1005348, doi:10.1371/journal.pcbi.1005348 (2017).
Miles, A. *et al.* Indels, structural variation, and recombination drive genom 13, Miles, A. *et al.* Indels, structural variation, and recombina
Plasmodium falciparum. *Genome research* **26**, 1288-1299
(2016).
Dewasurendra, R. L. *et al.* Use of a Plasmodium vivax gen
surveillance and parasite track
- Frames, A. et al. Indels, structural variation, and recombination drive genomic diversity in
Plasmodium falciparum. Genome research **26**, 1288-1299, doi:10.1101/gr.203711.115
(2016).
Dewasurendra, R. L. et al. Use of a Pla
- Plasmodium falciparum. Genome research 26, 1288-1299, doi:10.1101/gr.209711.115
(2016).
Dewasurendra, R. L. *et al.* Use of a Plasmodium vivax genetic barcode for genomic
surveillance and parasite tracking in Sri Lanka. *M* (2016).
Dewasurendra, R. L. *et al.* Use of a Plasmodium vivax genetic barcode for genomic
surveillance and parasite tracking in Sri Lanka. *Malaria journal* **19**, 342,
doi:10.1186/s12936-020-03386-3 (2020).
Ba, H. *et al.* Sa Dewasurendra, R. L. et al. Ose of a Frasmodium vivax generic barcode for genomic
surveillance and parasite tracking in Sri Lanka. *Malaria journal* 19, 342,
doi:10.1186/s12936-020-03386-3 (2020).
Ba, H. *et al.* Multi-l
- surveillance and parasite tracking in Sri Lanka. Malaria journal 19, 342,
doi:10.1186/s12936-020-03386-3 (2020).
Ba, H. *et al.* Multi-locus genotyping reveals established endemicity of a
distinct Plasmodium vivax populati Ba, H. *et al.* Multi-locus genotyping reveal
distinct Plasmodium vivax population in M
diseases 14, e0008945, doi:10.1371/journ
Schaffner, S. F., Taylor, A. R., Wong, W., W
infer pairwise identity by descent betweer
doi 39 Ba, H. et al. Matri-locus genotyping reveals established endemicity of a geographically
distinct Plasmodium vivax population in Mauritania, West Africa. *PLoS neglected tropic
diseases* **14**, e0008945, doi:10.1371/journ diseases 14, e0008945, doi:10.1371/journal.phtd.0008945 (2020).
Schaffner, S. F., Taylor, A. R., Wong, W., Wirth, D. F. & Neafsey, D. E. hmmlBD: software t
infer pairwise identity by descent between haploid genotypes. *Mal* diseases 14, e0008949, doi:10.1371/journal.pntd.0008949 (2020).
Schaffner, S. F., Taylor, A. R., Wong, W., Wirth, D. F. & Neafsey, D. I
infer pairwise identity by descent between haploid genotypes. Mai
doi:10.1186/s12936-0
- For pairwise identity by descent between haploid genotypes. *Malaria journal* 17, 196,
doi:10.1186/s12936-018-2349-7 (2018).
Battle, K. E. *et al.* Mapping the global endemicity and clinical burden of Plasmodium vivax,
200 infer pairwise identity by descent between haploid genotypes. Malarid Journal 17, 156,
doi:10.1186/s12936-018-2349-7 (2018).
Battle, K. E. *et al.* Mapping the global endemicity and clinical burden of Plasmodium viva
2000-Battle, K. E. *et al.* Mapping the global end
2000-17: a spatial and temporal modellin
6736(19)31096-7 (2019). Battle, K. E. et al. Mapping the global endemicity and clinical burden of Plasmodium vivax,
2000-17: a spatial and temporal modelling study. *Lancet* **394**, 332-343, doi:10.1016/S0140-
6736(19)31096-7 (2019). 2000-17: a spatial and temporal modelling study. *Lancet* 394, 332-343, doi:10.1016/S0140-
6736(19)31096-7 (2019). $\frac{1}{3}$

Chromosomal position (base pair)

Simulated sample pair index per data-generating

a. Global Microhaplotype PCoA

b.

Malaysia: Microhaplotype IBD

C.

 1.0 0.8 0.6 $\sum_{0.4}$ MODEL $BB38$ $GFO33$ 0.2 $GEO50$ GEO55 MHAP-3_10 0.0 Papua Mew Guinea Rent Million Afon_{lanti}col Bangladesh **British** Madagascar
Madascar
Madagasia Itemany **Bhutan** Cambooti, Corporation Entrance Indonessie Iran Mexico Mannar Reid Thailand India Sudan